Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.4.35 - 3',5'-cyclic-GMP phosphodiesterase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Effects of sildenafil citrate and etanercept treatment on TNF-? levels in peripheral blood of women with recurrent miscarriage.
Effects of Sildenafil Citrate and Heparin Treatments on Placental Cell Morphology in a Murine Model of Pregnancy Loss.
Acidosis
Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Acquired Immunodeficiency Syndrome
A nationwide population study of trazodone use in urology patients.
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Hypogonadism and erectile dysfunction as harbingers of systemic disease.
Long-term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted radical prostatectomy (RARP).
Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
Survival, Continence and Potency (SCP) recovery after radical retropubic prostatectomy: a long-term combined evaluation of surgical outcomes.
Acute Coronary Syndrome
Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference.
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Acute Kidney Injury
Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.
Phosphodiesterase-5 inhibition prevents postcardiopulmonary bypass acute kidney injury in swine.
Acute Lung Injury
Effects of phosphodiesterase 5 inhibitor sildenafil on the respiratory parameters, inflammation and apoptosis in a saline lavage-induced model of acute lung injury.
Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.
Adenocarcinoma
Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells.
Adenoma
Human thyroid cyclic nucleotide phosphodiesterase. Its characterization and the effect of several hormones on the activity.
Adenomatous Polyposis Coli
Exisulind Cell Pathways.
Albinism
FVB.129P2-Pde6b(+) Tyr(c-ch)/Ant, a sighted variant of the FVB/N mouse strain suitable for behavioral analysis.
Albuminuria
Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.
Alopecia
Risk of erectile dysfunction associated with use of 5-? reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.
Treatment review for male pattern hair-loss.
Altitude Sickness
Meta-analysis of clinical efficacy of sildenafil, a phosphodiesterase type-5 inhibitor on high altitude hypoxia and its complications.
Re: ''Meta-Analysis of Clinical Efficacy of Sildenafil, a Phosphodiesterase Type-5 Inhibitor on High Altitude Hypoxia and Its Complications" by Xu et al.
Systematic Review of the Effects of Phosphodiesterase-5 Inhibitors and Dexamethasone on High Altitude Pulmonary Edema (HAPE).
Alzheimer Disease
Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line.
Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease.
Design, synthesis, and biological evaluation of first-in-class dual acting histone deacetylases (HDACs) and phosphodiesterase 5 (PDE5) inhibitors for the treatment of Alzheimer's disease.
Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.
Discovery of in-vivo chemical probes for treating Alzheimer´s disease: Dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitors.
Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice.
Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling.
Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease.
Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5).
Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model.
Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-? peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer's disease.
Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis.
Sildenafil for the Treatment of Alzheimer's Disease: A Systematic Review.
Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Amnesia
The phosphodiesterase 5 inhibitor, KJH-1002, reverses a mouse model of amnesia by activating a cGMP/cAMP response element binding protein pathway and decreasing oxidative damage.
Amnesia, Transient Global
Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
Anemia, Sickle Cell
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease.
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism.
Potential utility of full-spectrum antioxidant therapy, citrulline, and dietary nitrate in the management of sickle cell disease.
Recurrent Priapism in a Military Veteran Receiving Treatment for PTSD.
Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation.
Aneurysm, Dissecting
Type B aortic dissection after the use of tadalafil.
Angina Pectoris
Dipyridamole inhibits intracellular calcium transients in isolated rat arteriole smooth muscle cells.
Serum cyclic 3',5'-nucleotide phosphodiesterase activity in myocardial infarction.
Sexual function in patients with chronic angina pectoris.
Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.
Antiphospholipid Syndrome
Treatment Algorithms in Systemic Lupus Erythematosus.
Aortic Valve Stenosis
Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis.
Arrhythmias, Cardiac
Effects of phosphodiestrase type 5 inhibitors in epinephrine-induced arrhythmia in rats: Involvement of lactate dehydrogenase and creatine kinase downregulation and adiponectin expression.
Arteriovenous Malformations
Inhaled nitric oxide and sildenafil therapy for a pediatric patient with multiple pulmonary arteriovenous malformations.
Arthritis
Effect of phosphodiesterase-5 inhibition on joint and muscle damage in rats with adjuvant arthritis
Treatment Algorithms in Systemic Lupus Erythematosus.
Asthma
A single dose of Sildenafil does not enhance FeNO: A randomised, cross-over and placebo-controlled study.
[Cyclic nucleotides phosphodiesterase activity in a rat lung model of asthma]
Atherosclerosis
Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems.
Mechanisms of enhanced vasoconstriction in the mouse model of atherosclerosis: the beneficial effects of sildenafil.
Molecular and Histologic Evidence of Novel Erectile Dysfunction Rat Model as an Aging Atherosclerosis Model: A Preliminary Study.
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.
Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.
Sildenafil (Viagra®) Prevents Cox-1/ TXA2 Pathway-Mediated Vascular Hypercontractility in ApoE-/- Mice.
Atrial Fibrillation
Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction.
Autoimmune Diseases
Sildenafil Counteracts the In Vitro Activation of CXCL-9, CXCL-10 and CXCL-11/CXCR3 Axis Induced by Reactive Oxygen Species in Scleroderma Fibroblasts.
Azotemia
The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA).
beta-Thalassemia
Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report.
Blindness
Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse.
AIPL1, the protein that is defective in Leber congenital amaurosis, is essential for the biosynthesis of retinal rod cGMP phosphodiesterase.
Apoptosis, retinitis pigmentosa, and degeneration.
Exclusion of five subunits of cGMP phosphodiesterase in Leber's congenital amaurosis.
Hippocampal synaptic plasticity in mice carrying the rd mutation in the gene encoding cGMP phosphodiesterase type 6 (PDE6).
Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase.
Retinal imaging in inherited retinal diseases.
Targeting iodothyronine deiodinases locally in the retina is a therapeutic strategy for retinal degeneration.
Blister
The identification of (-)-trans-tadalafil, tadalafil, and sildenafil in counterfeit Cialis((R)) and the optical purity of tadalafil stereoisomers.
Brain Injuries
Cyclic GMP phosphodiesterase inhibition alters the glial inflammatory response, reduces oxidative stress and cell death and increases angiogenesis following focal brain injury.
Neuroprotective effects of tadalafil on gerbil dopaminergic neurons following cerebral ischemia.
Brain Injuries, Traumatic
Phosphodiesterase-5 inhibition potentiates cerebrovascular reactivity in chronic traumatic brain injury.
Brain Ischemia
Acute Effect of Intravenous Sildenafil on Cerebral Blood Flow in Patients with Vasospasm After Subarachnoid Hemorrhage.
Brain Neoplasms
Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.
Breast Neoplasms
Effect of sildenafil on human aromatase activity: From in vitro structural analysis to catalysis and inhibition in cells.
Exisulind Cell Pathways.
Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy.
Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells.
Identification of a RAPD marker linked to progressive rod-cone degeneration in dogs.
Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.
Inhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468.
Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression.
Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G.
Bronchopulmonary Dysplasia
Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.
Carcinogenesis
Erratum: Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC.
Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC.
Repurposing mechanistic insight of PDE-5 inhibitor in cancer chemoprevention through mitochondrial-oxidative stress intervention and blockade of DuCLOX signalling.
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Carcinoma
cGMP phosphodiesterase activity evaluation in human carcinoma of salivary glands.
Cyclic guanosine monophosphate phosphodiesterase activity in human gingival carcinoma.
Does cyclic guanosine monophosphate induce autophagy in thyroid malignant carcinoma through down-regulation of cyclic guanosine monophosphate phosphodiesterase?
Essential role of the cGMP/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells.
Expression of iNOS--a favourable prognostic marker for early-stage carcinoma of the uterine cervix.
Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells.
The hypertensive effect of sorafenib is abolished by sildenafil.
The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels.
Carcinoma, Hepatocellular
Increased guanylate cyclase activity and guanosine 3',5'-monophosphate content in ethionine-induced hepatomas.
The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression.
Carcinoma, Papillary
Does cyclic guanosine monophosphate induce autophagy in thyroid malignant carcinoma through down-regulation of cyclic guanosine monophosphate phosphodiesterase?
Carcinoma, Renal Cell
The hypertensive effect of sorafenib is abolished by sildenafil.
Carcinoma, Squamous Cell
The Potential Role of Sildenafil in Cancer Management through EPR Augmentation.
Cardiomegaly
Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy.
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
An MRTF-A-Sp1-PDE5 Axis Mediates Angiotensin-II-Induced Cardiomyocyte Hypertrophy.
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A.
Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic Peptide signaling.
Phosphodiesterase 5 Associates With ?2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts.
Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway.
Pulmonary vascular and cardiac effects of peroxynitrite decomposition in newborn rats.
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice.
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Sildenafil and Cardioprotection.
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.
The ability of phosphodiesterase-5 inhibitors sildenafil and ordonafil to reverse L-NAME induced cardiac hypertrophy in the rabbit: possible role of calcineurin and p38.
Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy.
Cardiomyopathies
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.
Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
Tadalafil prevents acute heart failure with reduced ejection fraction in mice.
Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.
Cardiomyopathy, Hypertrophic
Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy.
Cardiotoxicity
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.
Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins.
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.
Cardiovascular Diseases
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio(®) ) in cardiac surgery: the REVAKI-1 study.
Beneficial Morphofunctional Changes Promoted by Sildenafil in Resistance Vessels in the Angiotensin II-Induced Hypertension Model.
Cardiac uses of phosphodiesterase-5 inhibitors.
Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function.
Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor ?-induced Smad signaling.
E-pharmacophore based virtual screening for identification of dual specific PDE5A and PDE3A inhibitors as potential leads against cardiovascular diseases.
Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training.
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference.
Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus.
Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease.
Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil.
Gender differences and dose proportionality in the toxicokinetics of udenafil and its active metabolite following oral administration in rodents.
Local condiments from fermented tropical legume seeds modulate activities of critical enzymes relevant to cardiovascular diseases and endothelial function.
Modulatory effect of some citrus (Citrus limon, Citrus reticulata, Citrus maxima) peels on monoamine oxidase, phosphodiesterase-5 and angiotensin-1 converting enzyme activities in rat heart homogenate.
Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters.
Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Phosphodiesterase 5 inhibition: effects on the coronary vasculature.
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine.
Serum cyclic 3',5'-nucleotide phosphodiesterase activity in myocardial infarction.
Sexual activity and cardiovascular disease.
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
The penis as a barometer of endothelial health.
The Phosphodiesterase-5 Inhibitor Vardenafil Improves the Activation of BMP Signaling in Response to Hydrogen Peroxide.
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells.
The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine.
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection.
Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
[Cardiovascular disease and sexuality]
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Catalepsy
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
Cataract
Nonarteritic anterior ischaemic optic neuropathy.
Central Serous Chorioretinopathy
Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study.
Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review.
Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?
THE EFFECTS OF SILDENAFIL CITRATE ON CHOROIDAL THICKNESS AS DETERMINED BY ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY.
[Serous central chorioretinopathy and tadalafil: A case report.]
Cerebral Hemorrhage
A Case of Recurrent Lobar Intracerebral Hemorrhage in the Setting of Phosphodiesterase-5 Inhibitor Use.
Cholera
Functional modifications of transducin induced by cholera or pertussis-toxin-catalyzed ADP-ribosylation.
Inhibition of guanylate cyclase and cyclic GMP phosphodiesterase by cholera toxin.
Light activation of phospholipase A2 in rod outer segments of bovine retina and its modulation by GTP-binding proteins.
Signal transduction via the B cell antigen receptor: involvement of a G protein and regulation of signaling.
Ciliopathies
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Membrane protein transport in photoreceptors: the function of PDE?: the Proctor lecture.
Retinal remodeling.
Cluster Headache
Sildenafil can induce the onset of a cluster headache bout.
Sildenafil can trigger cluster headaches.
Colitis
Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC.
The effect of phosphodiesterase-5 inhibition by sildenafil citrate on inflammation and apoptosis in rat experimental colitis.
Coloboma
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Colonic Neoplasms
Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G.
Mutations of the PDE5A Gene Confer a Survival Advantage in Patients with Colon Cancer.
Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC.
Phosphodiesterase-5 inhibitors for colon cancer chemoprevention.
Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective.
The enduring promise of phosphodiesterase 5 inhibitors for colon cancer prevention.
Color Vision Defects
A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene.
A nonhuman primate model of inherited retinal disease.
Characterization of Retinal Structure in ATF6-Associated Achromatopsia.
Clinical and genetic investigation of a large Tunisian family with complete achromatopsia: identification of a new nonsense mutation in GNAT2 gene.
Congenital Achromatopsia and Macular Atrophy Caused by a Novel Recessive PDE6C Mutation (p.E591K).
Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia.
Deep Phenotyping of PDE6C-Associated Achromatopsia.
Distinct patterns of compartmentalization and proteolytic stability of PDE6C mutants linked to achromatopsia.
Generation of an induced pluripotent stem cell line (FRIMOi007-A) derived from an incomplete achromatopsia patient carrying a novel homozygous mutation in PDE6C gene.
Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration.
Molecular Genetics of Achromatopsia in Newfoundland Reveal Genetic Heterogeneity, Founder Effects and the First Cases of Jalili Syndrome in North America.
Mutations in the gene PDE6C encoding the catalytic subunit of the cone photoreceptor phosphodiesterase in patients with achromatopsia.
Novel Bi-allelic PDE6C Variant Leads to Congenital Achromatopsia.
Novel mutations in the gene for ?-subunit of retinal cone cyclic nucleotide-gated channels in a Japanese patient with congenital achromatopsia.
PDE6C: Novel Mutations, Atypical Phenotype, and Differences Among Children and Adults.
Targeting iodothyronine deiodinases locally in the retina is a therapeutic strategy for retinal degeneration.
Two novel PDE6C gene mutations in Chinese family with achromatopsia.
Colorectal Neoplasms
No association between use of phosphodiesterase 5 inhibitors and colorectal cancer in men with erectile dysfunction.
Phosphodiesterase 5 Inhibitor Use and Risk of Conventional and Serrated Precursors of Colorectal Cancer.
Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis.
Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer.
Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.
Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice.
Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.
The Association Between Phosphodiesterase-5 Inhibitors and Colorectal Cancer in a National Cohort of Patients.
Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms.
Coma
Potentially fatal new trend in performance enhancement: a cautionary note on nitrite.
Complex Regional Pain Syndromes
Effect of tadalafil on blood flow, pain, and function in chronic cold Complex Regional Pain Syndrome: a randomized controlled trial.
Cone Dystrophy
A substitution of G to C in the cone cGMP-phosphodiesterase gamma subunit gene found in a distinctive form of cone dystrophy.
PDE6C: Novel Mutations, Atypical Phenotype, and Differences Among Children and Adults.
Cone-Rod Dystrophies
Longitudinal Clinical Follow-up and Genetic Spectrum of Patients With Rod-Cone Dystrophy Associated With Mutations in PDE6A and PDE6B.
PDE6C: Novel Mutations, Atypical Phenotype, and Differences Among Children and Adults.
Retinal imaging in inherited retinal diseases.
Congenitally Corrected Transposition of the Great Arteries
Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular size and function - A multi-center, double-blind, randomized, placebo-controlled clinical trial - SERVE trial - Rational and design.
Connective Tissue Diseases
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Coronary Artery Disease
Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers.
Effects of tadalafil on myocardial blood flow in patients with coronary artery disease.
Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment.
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.
Identification of a Functional PDE5A Variant at the Chromosome 4q27 Coronary Artery Disease Locus in an Extended Myocardial Infarction Family.
Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease.
Internal pudendal artery stenoses and erectile dysfunction: Correlation with angiographic coronary artery disease.
Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease.
Sexual function in patients with chronic angina pectoris.
Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study.
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.
The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Vacuum Erection Devices Revisited: Its Emerging Role in the Treatment of Erectile Dysfunction and Early Penile Rehabilitation Following Prostate Cancer Therapy.
Vacuum erection devices to treat erectile dysfunction and early penile rehabilitation following radical prostatectomy.
[The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease]
Coronary Disease
Commentaries on Jackson et al. "Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction".
Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease.
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.
Sildenafil: emerging cardiovascular indications.
Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction.
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.
The Safety of Preoperative Vardenafil in Patients Undergoing Coronary Artery Bypass Graft Surgery.
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Coronary Occlusion
Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition.
Coronary Thrombosis
Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition.
Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
COVID-19
Addressing male sexual and reproductive health in the wake of COVID-19 outbreak.
Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review).
Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.
Cranial Nerve Diseases
A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
Cystic Fibrosis
Classical activation of macrophages and vardenafil.
Inhaled PDE5 inhibitors restore chloride transport in cystic fibrosis mice.
Inhaled phosphodiesterase type 5 inhibitors for cystic fibrosis: a new therapy for systemic disease?
Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis.
Phosphodiesterase 5 inhibitors and cystic fibrosis: correcting chloride channel dysfunction.
Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis.
Death, Sudden, Cardiac
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Dementia
Role of sildenafil in neurological disorders.
Dementia, Vascular
Ameliorative effect of Phosphodiesterase-5 inhibitor in Rat model of Vascular Dementia.
Sildenafil treatment of vascular dementia in aged rats.
Tadalafil ameliorates memory deficits, oxidative stress, endothelial dysfunction and neuropathological changes in rat model of hyperhomocysteinemia induced vascular dementia.
Demyelinating Diseases
Phosphodiesterase-5 inhibition promotes remyelination by MCP-1/CCR-2 and MMP-9 regulation in a cuprizone-induced demyelination model.
Dermatitis, Atopic
Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.
Diabetes Mellitus
Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.
Baicalein Alleviates Erectile Dysfunction Associated With Streptozotocin-Induced Type I Diabetes by Ameliorating Endothelial Nitric Oxide Synthase Dysfunction, Inhibiting Oxidative Stress and Fibrosis.
Current diagnosis and management of erectile dysfunction.
Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Early administration of phosphodiesterase 5 inhibitors after induction of diabetes in a rat model may prevent erectile dysfunction.
Effect of phosphodiesterase-5 inhibitors on glycemic control in person with type 2 diabetes mellitus: A systematic review and meta-analysis.
Expression of myosin isoforms in the smooth muscle of human corpus cavernosum.
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.
Increased Phosphodiesterase Type 5 Levels in a Mouse Model of Type 2 Diabetes Mellitus.
Management of erectile dysfunction.
Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.
Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial.
Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial.
Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men.
The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.
The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis.
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
[Efficacy and safety of phosphodiesterase inhibitors for erectile dysfunction in diabetic men: A meta analysis].
Diabetes Mellitus, Experimental
Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus.
The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.
Diabetes Mellitus, Type 1
Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction.
Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.
Diabetes Mellitus, Type 2
Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes.
Correcting imbalance of sex hormones by a phosphodiesterase 5 inhibitor improves copulatory dysfunction in male rats with type 2 diabetes.
Effect of phosphodiesterase-5 inhibitors on glycemic control in person with type 2 diabetes mellitus: A systematic review and meta-analysis.
Increased Phosphodiesterase Type 5 Levels in a Mouse Model of Type 2 Diabetes Mellitus.
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.
Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial.
Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
Testosterone therapy for sexual dysfunction in men with Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.
Diabetic Cardiomyopathies
Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging.
Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition.
Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.
The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence.
Diabetic Foot
A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors.
Diabetic Nephropathies
Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors.
Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.
Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7.
Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats.
Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats.
Diabetic Neuropathies
Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?
Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy.
Seminal vesicles and diabetic neuropathy: ultrasound evaluation after prolonged treatment with a selective phosphodiesterase-5 inhibitor.
Down Syndrome
Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease.
Drug-Related Side Effects and Adverse Reactions
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
ADMET considerations for phosphodiesterase-5 inhibitors.
Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999.
Side effects reported by European consumers for medications for erectile dysfunction.
Dyskinesias
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Dyslipidemias
Efficacy of Phosphodiesterase Type 5 Inhibitor Treatment in Men with Erectile Dysfunction and Dyslipidemia: A Post Hoc Analysis of the Vardenafil Statin Study.
Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins.
Vardenafil in men with stable statin therapy and dyslipidemia.
Dyspnea
Perinatal Management and Long-Term Follow-up of a Primipara With Severe Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus.
Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report.
Eisenmenger Complex
A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study.
Dyspnea in Eisenmenger syndrome and its amelioration by sildenafil: role of J receptors.
Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.
Embolic Stroke
Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor.
Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
Encephalomyelitis
Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions.
Sildenafil Alleviates Murine Experimental Autoimmune Encephalomyelitis by Triggering Autophagy in the Spinal Cord.
Encephalomyelitis, Autoimmune, Experimental
Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions.
Sildenafil Alleviates Murine Experimental Autoimmune Encephalomyelitis by Triggering Autophagy in the Spinal Cord.
Epilepsy
Effect of sildenafil, a selective phosphodiesterase 5 inhibitor, on the anticonvulsant action of some antiepileptic drugs in the mouse 6-Hz psychomotor seizure model.
Sildenafil influences the anticonvulsant activity of vigabatrin and gabapentin in the timed pentylenetetrazole infusion test in mice.
Epistaxis
Epistaxis after PDE-5 inhibitors misuse.
Phosphodiesterase-5 Inhibitor Use: An Under-reported Cause of Profuse Nasal Bleeding.
Erectile Dysfunction
"Doc, if it were you, what would you do?": a survey of Men's Health specialists' personal preferences regarding treatment modalities.
3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues.
3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
8-Aryl xanthines potent inhibitors of phosphodiesterase 5.
A "real life" investigation on the prescriptive habits among Italian andrologists: The "CONSER" survey from Italian Society of Andrology (SIA) on Sildenafil oral film.
A 6-Month, Prospective, Observational Study of PDE5 Inhibitor Treatment Persistence and Adherence in Latin American Men with Erectile Dysfunction.
A case of acute pulmonary thromboembolism after taking tadalafil.
A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction.
A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.
A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction.
A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.
A fully validated method for the determination of vardenafil in blood using gas chromatography/mass spectrometry.
A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With ?-Blockers and ?-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction.
A meta-regression analysis of treatment effect modifiers in trials with flexible-dose oral sildenafil for erectile dysfunction in broad-spectrum populations.
A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction.
A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.
A multifaceted approach to maximize erectile function and vascular health.
A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors.
A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide.
A novel aphrodisiac compound from an orchid that activates nitric oxide synthases.
A novel approach to simultaneous screening and confirmation of regulated pharmaceutical compounds in dietary supplements by LC/MS/MS with an information-dependent acquisition method.
A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.
A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction.
A Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) inhibitor, in healthy male volunteers.
A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder.
A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction.
A protein tyrosine kinase inhibitor, imatinib mesylate (gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats.
A Proteomic Analysis Using an Animal Model for Hyperlipidemia-related Erectile Dysfunction.
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction.
A Review of Current and Emerging Therapeutic Options for Erectile Dysfunction.
A study of the management of erectile dysfunction in general practice.
A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with ?-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
A Systematic Review Assessing the Economic Impact of Sildenafil Citrate (Viagra(®) ) in the Treatment of Erectile Dysfunction.
A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex?
Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
Accurate mass measurement using Fourier transform ion cyclotron resonance mass spectrometry for structure elucidation of designer drug analogs of tadalafil, vardenafil and sildenafil in herbal and pharmaceutical matrices.
ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction.
Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.
Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients.
Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes.
Acute dysphonia secondary to vocal fold hemorrhage after vardenafil use.
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction.
Acute Hemodynamic Changes after Single Administration of Udenafil in Pulmonary Arterial Hypertension: a Phase IIa Study.
Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.
Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors?
Adulteration of herbal sexual enhancers and slimmers: The wish for better sexual well-being and perfect body can be risky.
Advances in the Management of Post-Radical Prostatectomy Erectile Dysfunction: Treatment Strategies When PDE-5 Inhibitors Don't Work.
Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue.
Age at First Presentation for Erectile Dysfunction: Analysis of Changes over a 12-yr Period.
Aggressive behavior increases after termination of chronic sildenafil treatment in mice.
Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors.
Alterations in the phosphodiesterase type 5 pathway and oxidative stress correlate with erectile function in spontaneously hypertensive rats.
An algorithm for medical management in male lower urinary tract symptoms.
An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction.
An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries.
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.
An open trial of oral sildenafilin antidepressant-induced sexual dysfunction.
An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.
An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects.
An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.
An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
An update on the drug safety of treating erectile dysfunction.
Analysis of pharmacological mechanisms of Yinyanghuo as treatment of erectile dysfunction with network pharmacology-based strategy.
Androgen deficiency in the etiology and treatment of erectile dysfunction.
Animal models in urological disease and sexual dysfunction.
Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis.
Application of high-performance liquid chromatography with charged aerosol detection for universal quantitation of undeclared phosphodiesterase-5 inhibitors in herbal dietary supplements.
Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction.
Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis.
Are Phosphodiesterase Type 5 Inhibitors Associated with Vision-Threatening Adverse Events? A Critical Analysis and Review of the Literature.
Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Arterial erectile dysfunction: Different severities of endothelial apoptosis between diabetic patients "responders" and "non responders" to sildenafil.
Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach.
Assessing satisfaction in men and their female partners after treatment with phosphodiesterase type 5 inhibitors for erectile dysfunction.
Assessing satisfaction in men with premature ejaculation after dapoxetine treatment in real-world practice.
Assessing the Variability in Insurance Coverage Transparency for Male Sexual Health Conditions in the United States.
Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study.
Assessment of the effect of mirodenafil on the hemodynamics of healthy male korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study.
Assessment of the Efficacy of Combination Therapy with Folic Acid and Tadalafil for the Management of Erectile Dysfunction in Men with Type 2 Diabetes Mellitus.
Assisted semen collection using two phosphodiesterase type 5 inhibitors (Tadalafil and Sildenafil) in infertile men with mild erectile dysfunction.
Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.
Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms.
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.
Audiometry results and TEOAE and DPOAE amplitudes in men taking a phosphodiesterase type 5 inhibitor for erectile dysfunction.
Audiovisual Sexual Stimulation and RigiScan Test for the Diagnosis of Erectile Dysfunction.
Avanafil - a further step to tailoring patient needs and expectations.
Avanafil for male erectile dysfunction: a systematic review and meta-analysis.
Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.
Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.
Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles in retinal function and hemodynamics in anesthetized dogs.
Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
Avanafil: a review of its use in patients with erectile dysfunction.
BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo.
Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors.
Benefits of erectile function recovery programs after radical prostatectomy (Review).
Bilateral neurosensory retinal detachment secondary to tadalafil treatment.
Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers.
Bioequivalence study of sildenafil citrate tablets in healthy human volunteers.
Can an educational program optimize PDE5i therapy? A study of Canadian primary care practices.
Can low intensity shockwave therapy match the efficacy of phosphodiesterase-5 inhibitors for erectile dysfunction treatment? A pooled data analysis from two randomized clinical trials.
Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction.
Can phosphodiesterase type 5 inhibitors cure erectile dysfunction?
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Cardioprotection with sildenafil: implications for clinical practice.
Cardiovascular effects of phosphodiesterase 5 inhibitors.
Cardiovascular effects of phosphodiesterase type 5 inhibitors.
Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5).
Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
Cardiovascular Risk Factors Determine Erectile and Arterial Function Response to Sildenafil.
Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market.
Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
Carotid artery intima-media thickness can predict the response of patients with erectile dysfunction to phosphodiesterase 5 inhibitors.
Cavernous body reduction in four patients with erectile dysfunction due to insufficient venous occlusion and a deficit of elastic fibers in the tunica albuginea.
cDNA microarray analysis of differentially expressed genes in penile tissue after treatment with tadalafil.
Central serous chorioretinopathy due to tadalafil use.
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.
Challenges in sexual medicine.
Change of Erectile Function and Responsiveness to Phosphodiesterase Type 5 Inhibitors at Different Stages of Streptozotocin-Induced Diabetes in Rats.
Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
Characterization of TPN729 metabolites in humans using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes.
Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.
Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction.
Chronic Vardenafil Treatment Improves Erectile Function via Structural Maintenance of Penile Corpora Cavernosa in Rats with Acute Arteriogenic Erectile Dysfunction.
Classical activation of macrophages and vardenafil.
Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients.
Clinical evaluation of erectile dysfunction in the era of PDE-5 inhibitors.
Clinical monograph for drug formulary review: erectile dysfunction agents.
Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction.
Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Clinical use of sildenafil in pulmonary artery hypertension.
Coital hemorrhage of an arteriovenous malformation after premedication with tadalafil (cialis).
Color Doppler Duplex Ultrasound (CDDU) Parameters in Men without Organic Erectile Dysfunction.
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum.
Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue.
Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction.
Combination of Psychological Intervention and Phosphodiesterase-5 Inhibitors for Erectile Dysfunction: A Narrative Review and Meta-Analysis.
Combination of stromal vascular fraction and Ad-COMP-Ang1 gene therapy improves long-term therapeutic efficacy for diabetes-induced erectile dysfunction.
Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction.
Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil.
Combination therapy for erectile dysfunction: an update review.
Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis.
Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study.
Comment on "Efficacy and safety of oral phosphodiesterase 5 inhibitor for erectile dysfunction: a network meta-analysis and multicriteria decision".
Comorbid LUTS and erectile dysfunction: optimizing their management.
Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis.
Comparative Effects of Alkaloid Extracts from Aframomum melegueta (Alligator Pepper) and Aframomum danielli (Bastered Melegueta) on Enzymes Relevant to Erectile Dysfunction.
Comparative effects of sildenafil, phentolamine, yohimbine and L-arginine on the rabbit corpus cavernosum.
Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation.
Comparison of efficacy and safety of daily oral L-arginine and PDE5Is alone or combination in treating erectile dysfunction: A systematic review and meta-analysis of randomised controlled trials.
Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor Tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Comparison of sildenafil with strontium fructose diphosphate in improving erectile dysfunction against upregulated cavernosal NADPH oxidase, protein kinase C?, and endothelin system in diabetic rats.
Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer.
Compliance with Testosterone Replacement Therapy in Patients with Testosterone Deficiency Syndrome: A 10-Year Observational Study in Korea.
Computational Analysis of the Mechanism and Thermodynamics of Inhibition of Phosphodiesterase 5A by Synthetic Ligands.
Computational screening and design of traditional Chinese medicine (TCM) to block phosphodiesterase-5.
Condom Attitudes of Heterosexual Men Ages 50 and Older Using Prescribed Drugs (Viagra, Cialis, Levitra) to Treat Erectile Dysfunction.
Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.
Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction.
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil.
Correlations With Satisfaction Measures in Men Treated With Phosphodiesterase Inhibitors for Erectile Dysfunction.
Counseling patients about sexual issues.
Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks.
Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Current and Emerging Treatments for Premature Ejaculation.
Current concepts in the evaluation and management of erectile dysfunction.
Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.
Current management strategy of treating patients with erectile dysfunction after radical prostatectomy: a systematic review and meta-analysis.
Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
DA-8159 reverses selective serotonin reuptake inhibitor-induced erectile dysfunction in rats.
Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.
Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels.
Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.
Decision tree analyses of key patient characteristics in Middle Eastern/North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction.
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis.
Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse.
Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS-application to forensic and therapeutic drug monitoring cases.
Determination of Phosphodiesterase-5 Inhibitors and Analogs Using High-Performance Liquid Chromatography with Ultraviolet Detection.
Determination of sildenafil by preconcentration on surfactant coated polymeric resin followed by spectrofluorimetry.
Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection.
Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study.
Development and evaluation of an immunochromatographic strip for rapid screening of sildenafil-type compounds as illegal additives in functional foods.
Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction.
Development and validation of a dissolution test for lodenafil carbonate based on in vivo data.
Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood.
Development and validation of a GC/MS method for the determination of tadalafil in whole blood.
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification.
Development of a group-specific antibody-based immunoassay method for simultaneously detecting sildenafil-like adulterants in herbal spirit drinks.
Development of an immunoassay for rapid screening of vardenafil and its potential analogues in herbal products based on a group specific monoclonal antibody.
Development of an optimized avanafil-loaded invasomal transdermal film: Ex vivo skin permeation and in vivo evaluation.
Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study.
Development of spray-dried amorphous solid dispersions of tadalafil using glycyrrhizin for enhanced dissolution and aphrodisiac activity in male rats.
Diabetes and Sexuality.
Diabetes Exacerbates the Functional Deficiency of NO/cGMP Pathway Associated with Erectile Dysfunction in Human Corpus Cavernosum and Penile Arteries.
Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research.
Diagnosis and management of erectile dysfunction in the primary care setting.
Diagnosis and Treatment of Erectile Dysfunction for Reduction of Cardiovascular Risk.
Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Differentiation of human neuroblastoma cell line IMR-32 by sildenafil and its newly discovered analogue IS00384.
Direct androgen regulation of PDE5 gene or the lack thereof.
Direct effects of selective type 5 phosphodiesterase inhibitors alone or with other vasodilators on the erectile response in cats.
Direct-To-Consumer Internet Prescription Platforms Overlook Crucial Pathology Found During Traditional Office Evaluation of Young Men With Erectile Dysfunction.
Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.
Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure.
Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis.
Docking-based CoMFA and CoMSIA analyses of tetrahydro-?-carboline derivatives as type-5 phosphodiesterase inhibitors.
Does Current Scientific and Clinical Evidence Support the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Premature Ejaculation? A Systematic Review and Meta-analysis.
Does educational status affect a patient's behavior toward erectile dysfunction?
Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study.
Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?
Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernosal arteries? A pilot study.
Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation.
Drug combinations in the therapy of low response to phosphodiesterase 5 inhibitors in patients with erectile dysfunction.
Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.
Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling.
Early administration of phosphodiesterase 5 inhibitors after induction of diabetes in a rat model may prevent erectile dysfunction.
Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function.
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction.
Editorial comment on: chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction.
EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor.
Effect of a three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor on erectile dysfunction.
Effect of BKCa Channel Opener LDD175 on Erectile Function in an In Vivo Diabetic Rat Model.
Effect of Chronic Administration of PDE5 Combined with Glycemic Control on Erectile Function in Streptozotocin-Induced Diabetic Rats.
Effect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice.
Effect of DA-8159, a selective phosphodiesterase type 5 inhibitor, on electroretinogram and retinal histology in rabbits.
Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction.
Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction.
Effect of Intracavernous Administration of Angiopoietin-4 on Erectile Function in the Streptozotocin-Induced Diabetic Mouse.
Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects.
Effect of Nightly versus On-Demand Vardenafil on Recovery of Erectile Function in Men Following Bilateral Nerve-Sparing Radical Prostatectomy.
Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study.
Effect of phosphodiesterase-5 inhibitor on hearing.
Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis.
Effect of Phosphodiesterase-5 Inhibitors on the Treatment of Male Infertility: A Systematic Review and Meta-Analysis.
Effect of sildenafil (Viagra) on cerebral blood flow velocity: a pilot study.
Effect of sildenafil citrate on brain central fatigue after exhaustive swimming exercise in rats.
Effect of sildenafil in cavernous arteries of patients with erectile dysfunction.
Effect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in mice.
Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats.
Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US.
Effect of Tadalafil on Seizure Threshold and Activity of Antiepileptic Drugs in Three Acute Seizure Tests in Mice.
Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dysfunction in the anesthetized dog.
Effectiveness of intracavernous delivery of adenovirus encoding Smad7 gene on erectile function in a mouse model of cavernous nerve injury.
Effectiveness of Intracavernous Delivery of Recombinant Human Hepatocyte Growth Factor on Erectile Function in the Streptozotocin-Induced Diabetic Mouse.
Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats.
Effects of chronic type 5 phosphodiesterase inhibition on penile microvascular reactivity in hypertensive patients with erectile dysfunction: a randomized crossover placebo-controlled trial.
Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.
Effects of hydrogen sulfide on erectile function and its possible mechanism(s) of action.
Effects of Once-Daily Tadalafil on Treatment Satisfaction, Psychosocial Outcomes, Spontaneous Erections, and Measures of Endothelial Function in Men With Erectile Dysfunction But Naive to Phosphodiesterase Type 5 Inhibitors.
Effects of Phosphodiesterase Inhibitors on the Inflammatory Response of Endothelial Cells Stimulated by Myeloperoxidase-Modified Low-Density Lipoprotein or Tumor Necrosis Factor Alpha.
Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil.
Effects of sildenafil citrate on human hemodynamics.
Effects of sildenafil citrate on peripheral fatigue and exercise performance after exhaustive swimming exercise in rats.
Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue.
Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation.
Effects of sildenafil on pentylenetetrazol-induced convulsions in mice and amygdala-kindled seizures in rats.
Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training.
Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.
Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro.
Effects of systemic tadalafil on skin flap survival in rats.
Effects of tadalafil on myocardial blood flow in patients with coronary artery disease.
Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Efficacy and safety of avanafil 200 mg versus sildenafil 100 mg in the treatment of erectile dysfunction after robot-assisted unilateral nerve-sparing prostatectomy: A prospective multicentre study.
Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial.
Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil.
Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study.
Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease.
Efficacy and safety of medium and long-term tadalafil use in spinal cord patients with erectile dysfunction.
Efficacy and Safety of Mirodenafil in Men Taking Antihypertensive Medications.
Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction.
Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study.
Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men.
Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Efficacy and Safety of Oral Mirodenafil in the Treatment of Erectile Dysfunction in Diabetic Men in Korea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial.
Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.
Efficacy and Safety of Sildenafil by Age in Men With Erectile Dysfunction.
Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.
Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.
Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies.
Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study.
Efficacy and Safety of Tadalafil for Erectile Dysfunction in Patients with Multiple Sclerosis.
Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.
Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.
Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.
Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial.
Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial.
Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.
Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction.
Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study.
Efficacy of Phosphodiesterase Type 5 Inhibitor Treatment in Men with Erectile Dysfunction and Dyslipidemia: A Post Hoc Analysis of the Vardenafil Statin Study.
Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
Efficacy of Udenafil for the Treatment of Erectile Dysfunction up to 12 Hours after Dosing: A Randomized Placebo-Controlled Trial.
Efficiency of combined therapy with impaza and type 5 phosphodiesterase inhibitors in prophylactics of posttraumatic erectile dysfunction.
Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadism.
Eight challenges faced by general practitioners caring for patients after an acute coronary syndrome.
Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction.
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Emerging pharmacologic approaches for the treatment of lower urinary tract disorders.
Endothelial Antioxidant Administration Ameliorates the Erectile Response to PDE5 Regardless of the Extension of the Atherosclerotic Process.
Endothelial dysfunction, erectile dysfunction and phosphodiesterase 5 inhibitors. An update of the current data and future perspectives.
Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage.
Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats.
Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs.
Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats.
Enzyme activities of the nitric oxide-cGMP pathway in corpus cavernosum isolated from middle-aged rats.
Erectile Dysfunction (ED) is a Shared Sexual Concern of Couples II: Association of Female Partner Characteristics with Male Partner ED Treatment Seeking and Phosphodiesterase Type 5 Inhibitor Utilization.
Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
Erectile dysfunction and cardiovascular considerations: managing patients effectively with phosphodiesterase type 5 inhibitors.
Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment.
Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins.
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.
Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men.
Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?
Erectile dysfunction in aging men: testosterone role in therapeutic protocols.
Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice.
Erectile dysfunction in patients taking psychotropic drugs and treated with phosphodiesterase-5 inhibitors.
Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels.
Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies.
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Erectile dysfunction.
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Erectile dysfunction: etiology, evaluation, and treatment options.
Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.
Erectile dysfunction: monitoring response to treatment in clinical practice--recommendations of an international study panel.
Erectile dysfunction: the role of penile Doppler ultrasound in diagnosis.
Erectile dysfunctions.
Erectile function after treatment for rhabdomyosarcoma of prostate and bladder.
Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection.
Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.
Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.
Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil.
Evaluation of combined therapeutic effects of hydrogen sulfide donor sodium hydrogen sulfide and phosphodiesterase type-5 inhibitor tadalafil on erectile dysfunction in a partially bladder outlet obstructed rat model.
Evaluation of neuroprotective and anti-fatigue effects of sildenafil.
Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos.
Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999.
Evaluation of therapeutic response of patients with erectile dysfunction.
Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?
Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.
Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors.
Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction.
Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.
Exploring the potentials of some compounds from Garcinia kola seeds towards identification of novel PDE-5 inhibitors in erectile dysfunction therapy.
Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum.
Extracorporeal Shock Waves Therapy Delivered by Aries Improves Erectile Dysfunction in Spontaneously Hypertensive Rats Through Penile Tissue Remodeling and Neovascularization.
Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil.
Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation.
Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Factors predicting outcomes of penile rehabilitation with udenafil 50?mg following radical prostatectomy.
Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges.
Fertility in men with spinal cord injury.
Fingerprinting of sildenafil citrate and tadalafil tablets in pharmaceutical formulations via X-ray fluorescence (XRF) spectrometry.
Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men.
FR226807: a potent and selective phosphodiesterase type 5 inhibitor.
Future prospects in the treatment of erectile dysfunction: focus on avanafil.
Gender differences and dose proportionality in the toxicokinetics of udenafil and its active metabolite following oral administration in rodents.
Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice.
Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis.
Ginseng for erectile dysfunction.
Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.
Hemodynamic effects of sildenafil in patients with stable ischemic heart disease.
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.
Hepatoprotective role of vardenafil against experimentally induced hepatitis in mice.
Herb-drug interaction of Epimedium sagittatum (Sieb. et Zucc.) maxim extract on the pharmacokinetics of sildenafil in rats.
High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
Histopathologic effect of chronic use of sildenafil citrate on the choroid & retina in male rats.
Histopathologic results of long-term sildenafil administration on rat inner ear.
Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians.
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians.
Hydrogen Sulfide and Urogenital Tract.
Hypogonadal Men Nonresponders to the PDE5 Inhibitor Tadalafil Benefit from Normalization of Testosterone Levels with a 1% Hydroalcoholic Testosterone Gel in the Treatment of Erectile Dysfunction (TADTEST Study).
Hypogonadism and erectile dysfunction as harbingers of systemic disease.
Icariin modulates eNOS activity via effect on post-translational protein-protein interactions to improve erectile function of spontaneously hypertensive rats.
Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling.
Identification of Erectile Dysfunction Drugs in Dietary Supplements by Liquid Chromatography Ion Trap Mass Spectrometry.
Identification of sildenafil, tadalafil and vardenafil by gas chromatography-mass spectrometry on short capillary column.
Immunolocalization of multidrug resistance protein 5 in the human genitourinary system.
Impact of a first treatment with phosphodiesterase inhibitors on men and partners' quality of sexual life: results of a prospective study in primary care.
Impact of aging and comorbidity on the efficacy of low-intensity shock wave therapy for erectile dysfunction.
Impact of phosphodiesterase type 5 inhibitor treatment on the rates of sexually transmitted diseases in a Veterans Affairs Medical Center patient population.
Improved flap viability with site-specific delivery of sildenafil citrate using fibrin glue.
Improved Sexual Function with Testosterone Replacement Therapy in Hypogonadal Men: Real-World Data from the Testim Registry in the United States (TRiUS).
Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study.
Improvement in symptoms of peripheral arterial disease with sildenafil therapy.
Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil.
Improvement of Sexual and Reproductive Function in Men with Spinal Cord Lesion.
In men with erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well-being.
In Vitro Fertilization Entails a High Prevalence of Erectile and Male Sexual Dysfunction: A Prospective Case-Control Study.
In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect.
In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.
Increased Phosphodiesterase Type 5 Levels in a Mouse Model of Type 2 Diabetes Mellitus.
Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction.
Inflatable penile prostheses for the treatment of erectile dysfunction.
Influence of Alcohol on Phosphodiesterase 5 inhibitors Use in Middle- to Old-Aged Men: A Comparative Study of Adverse Events.
Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea.
Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors.
Influence of the PDE5 inhibitor tadalafil on redox status and antioxidant defense system in C2C12 skeletal muscle cells.
Inhibition of Cyclic GMP Export by Multidrug Resistance Protein 4: A New Strategy to Treat Erectile Dysfunction?
Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling.
Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction.
Inhibition of proNGF and p75NTR Pathway Restores Erectile Function Through Dual Angiogenic and Neurotrophic Effects in the Diabetic Mouse.
Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves.
Instrumental neutron activation analysis (INAA) and liquid chromatography (LC) coupled to high resolution mass spectrometry (HRMS) characterisation of sildenafil based products seized on the Italian illegal market.
Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells.
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.
Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery.
Internal pudendal artery stenoses and erectile dysfunction: Correlation with angiographic coronary artery disease.
Interventions for sexual dysfunction following treatments for cancer.
Intracavernosal injections in the diagnosis and treatment of PDE-5 resistant erectile dysfunction.
Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse.
Intracavernous delivery of freshly isolated stromal vascular fraction rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse.
Intracavernous Delivery of Synthetic Angiopoietin-1 Protein as a Novel Therapeutic Strategy for Erectile Dysfunction in the Type II Diabetic db/db Mouse.
Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment.
Intracavernous pharmacotherapy for erectile dysfunction.
Investigation of the Presence of Sildenafil in Herbal Dietary Supplements by Validated HPLC Method.
Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.
Ion beam analysis (IBA) and instrumental neutron activation analysis (INAA) for forensic characterisation of authentic Viagra® and of sildenafil-based illegal products.
Is Inhibition of Phosphodiesterase Type-5 by Sildenafil a Promising Therapy for Volume Overload Heart Failure?
Is Penile Length a Factor in Treatment of Erectile Dysfunction with PDE-5 Inhibitor?
Is sex only for the healthy and wealthy?
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?
Isolation of two isoforms of phosphodiesterase 5 from rat penis.
JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
Key features for designing phosphodiesterase-5 inhibitors.
l-Cys/CSE/H2S pathway modulates mouse uterus motility and sildenafil effect.
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
Leber's hereditary optic neuropathy precipitated by tadalafil use for erectile dysfunction.
Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.
Letter to the Editor RE: Zotarolimus-Eluting Peripheral Stents for the Treatment of Erectile Dysfunction in Subjects with Suboptimal Response to Phosphodiesterase-5 Inhibitors.
Lingual mucosal graft in treatment of Peyronie disease.
Literature commentary.
Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders.
Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal.
Long-term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted radical prostatectomy (RARP).
Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence.
Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension.
Low-Intensity Extracorporeal Shock Wave as a Novel Treatment for Erectile Dysfunction.
Low-Intensity Extracorporeal Shockwave Therapy Can Improve Erectile Function in Patients Who Failed to Respond to Phosphodiesterase Type 5 Inhibitors.
Low-Intensity Shock Wave Therapy and Its Application to Erectile Dysfunction.
Low-Intensity Shockwave Therapy for Erectile Dysfunction: A Randomized Clinical Trial Comparing 2 Treatment Protocols and the Impact of Repeating Treatment.
Lower urinary tract symptoms and sexual dysfunction: a common approach.
Lower urinary tract symptoms in men.
Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors.
Male fertility following spinal cord injury: an update.
Management of sildenafil treatment failures.
Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach.
Managing the adverse effects of radiation therapy.
Mechanisms Involved in the Remyelinating Effect of Sildenafil.
Medical therapy for benign prostatic hyperplasia: a review.
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.
Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Medicinal Plants Used for the Treatment of Erectile Dysfunction in Ethiopia: A Systematic Review.
Melanocortins in the treatment of male and female sexual dysfunction.
Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
Metabotropic Glutamate Receptor Subtype 7 Is Essential for Ejaculation.
Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study.
Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature.
Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction.
Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction.
Modulation of thioacetamide-induced liver fibrosis/cirrhosis by sildenafil treatment.
Molecular and Histologic Evidence of Novel Erectile Dysfunction Rat Model as an Aging Atherosclerosis Model: A Preliminary Study.
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
Multiple roles of the messenger molecule cGMP in testicular function.
Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Nasal congestion after visual sexual stimulation with and without sildenafil (Viagra): a randomized placebo-controlled study.
NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide.
Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil.
Neurogenic Sexual Dysfunction Treatment: A Systematic Review.
New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil.
New oral drugs for erectile dysfunction.
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is).
Newer phosphodiesterase inhibitors: comparison with established agents.
No adverse hemodynamic interaction between sildenafil and red wine.
No association between use of phosphodiesterase 5 inhibitors and colorectal cancer in men with erectile dysfunction.
Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction.
Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction.
Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case.
Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress.
Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.
Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction.
Off-Label Use of Phosphodiesterase Type 5 Inhibitor Erectile Dysfunction Medication to Enhance Sex Among Gay and Bisexual Men in Australia: Results From the FLUX Study.
Optic atrophy after sildenafil use.
Optical coherence tomography in tadalafil-associated retinal toxicity.
Optimization of sexual function outcome after radical prostatectomy using phosphodiesterase type 5 inhibitors.
Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation.
Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health.
Oral L-citrulline and Transresveratrol Supplementation Improves Erectile Function in Men With Phosphodiesterase 5 Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study.
Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction.
Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis.
Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.
Oral phosphodiesterase-5 inhibitors and sperm functions.
Oral Testofen, L-Citrulline, Resveratrol, and Caffeine Supplement Drink Improves Sexual Function in Men with Phosphodiesterase 5 Inhibitors: Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study.
Osteopathic approach to sexual dysfunction: holistic care to improve patient satisfaction and prevent mortality and morbidity.
Overall cardiovascular profile of sildenafil citrate.
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Oxytocin is involved in the proconvulsant effects of Sildenafil: Possible role of CREB.
Oxytocinergic system mediates the proconvulsant effects of sildenafil: The role of calcineurin.
P144, A TGF-?1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats.
Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil.
Patients responding to phosphodiesterase type 5 inhibitor therapy: what do their sexual partners know?
Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy.
PDE-5 inhibitors for erectile dysfunction in men with diabetes.
PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction.
PDE-5 inhibitors in selected herbal supplements from the Ghanaian market for better erectile function as tested by a bioassay.
PDE-5 Inhibitors: Clinical Points.
PDE-5 inhibitors: current status and future trends.
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.
PDE5 inhibitors beyond erectile dysfunction.
PDE5 inhibitors for LUTS.
PDE5 inhibitors in non-urological conditions.
PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy.
Penile rehabilitation after radical prostatectomy: important therapy or wishful thinking?
Penile Rehabilitation: The "Up"-date.
Perceptions of Erectile Dysfunction and Phosphodiesterase Type 5 Inhibitor Therapy in a Qualitative Study of Men and Women in Affected Relationships.
Pericyte-Derived Dickkopf2 Regenerates Damaged Penile Neurovasculature Through an Angiopoietin-1-Tie2 Pathway.
Perspectives on urological care in multiple sclerosis patients.
Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.
Pharmacogenetics of erectile dysfunction: navigating into uncharted waters.
Pharmacokinetic and Bioequivalence Evaluation of 2 Tadalafil Tablets in Healthy Male Chinese Subjects Under Fasting and Fed Conditions.
Pharmacokinetic, metabolic stability, plasma protein binding and CYP450s inhibition/induction assessment studies of N-(2-pyridylmethyl)-2-hydroxiymethyl-1-pyrrolidinyl-4-(3-chloro-4-methoxy-benzylamino)-5-pyrimidine-carboxamide as potential type 5 phosphodiesterase inhibitors.
Pharmacokinetics and bioequivalence of sildenafil granules and sildenafil tablets in Korean healthy volunteers.
Pharmacokinetics of a New Orodispersible Tablet Formulation of Vardenafil: Results of Three Clinical Trials.
Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Pharmacologic treatment for pulmonary arterial hypertension.
Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression.
Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors.
Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.
Pharmacological treatment for premature ejaculation.
Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Pharmacology of phosphodiesterase-5 inhibitors.
Pharmacotherapy for erectile dysfunction.
Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.
Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction.
Phenanthrenes from Eulophia macrobulbon as Novel Phosphodiesterase-5 Inhibitors.
Phenolic analysis and erectogenic function of African Walnut (Tetracarpidium conophorum) seeds: The impact of the seed shell on biological activity.
Phosphodiesterase (PDE5) inhibition assay for rapid detection of erectile dysfunction drugs and analogs in sexual enhancement products.
Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies.
Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure.
Phosphodiesterase 5 inhibition: effects on the coronary vasculature.
Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.
Phosphodiesterase 5 inhibitors for erectile dysfunction.
Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Phosphodiesterase 5 Inhibitors from Derris scandens.
Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.
Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles.
Phosphodiesterase 5 inhibitors: current status and potential applications.
Phosphodiesterase inhibitors and the eye.
Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men.
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems.
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Phosphodiesterase type 5 in men with vasculogenic and post-radical prostatectomy erectile dysfunction: is there a molecular difference?
Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients.
Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms.
Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome.
Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Phosphodiesterase Type 5 Inhibitor Treatment for Erectile Dysfunction in Patients with End-Stage Renal Disease Receiving Dialysis or After Renal Transplantation.
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Phosphodiesterase Type 5 Inhibitors and Female Sexual Response: Faulty Protocols or Paradigms?
Phosphodiesterase type 5 inhibitors and kidney disease.
Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons.
Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action.
Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment.
Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.
Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men.
Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review.
Phosphodiesterase Type 5 Inhibitors in Postprostatectomy Erectile Dysfunction: A Critical Analysis of the Basic Science Rationale and Clinical Application.
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review.
Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis.
Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?
Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
Phosphodiesterase type 5 inhibitors: state of the therapeutic class.
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis.
Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.
Phosphodiesterase-5 Inhibitor Use: An Under-reported Cause of Profuse Nasal Bleeding.
Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Phosphodiesterase-5 Inhibitors Could Be Efficacious in the Treatment of Erectile Dysfunction after Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
Phosphodiesterase-5 inhibitors: future perspectives.
Phosphodiesterase-5 inhibitors: Shedding new light on the darkness of depression?
Phosphodiesterases 5 inhibitors and erectile dysfunction recovery after pelvic surgery: future perspectives for new drugs and new formulations.
Pituitary adenoma apoplexy associated with vardenafil intake.
Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis.
Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study.
Potential for Long-Term Benefit of Cognitive Behavioral Therapy as an Adjunct Treatment for Men with Erectile Dysfunction.
Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure.
Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate.
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Preconditioning of adipose-derived stem cells by phosphodiesterase-5 inhibition enhances therapeutic efficacy against diabetes-induced erectile dysfunction.
Predictors of response to sildenafil citrate following radiation therapy for prostate cancer.
Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens.
Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.
Preparation of sildenafil citrate microcapsules and in vitro/in vivo evaluation of taste masking efficiency.
Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats.
Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study.
Prevalence of erectile dysfunction oral drugs use in a city of southern Brazil.
Proconvulsant effects of sildenafil citrate on pilocarpine-induced seizures: Involvement of cholinergic, nitrergic and pro-oxidant mechanisms.
Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
Pulmonary embolism after tadalafil ingestion.
Randomised Trial of CPAP and Vardenafil on Erectile and Arterial Function in Men with Obstructive Sleep Apnea and Erectile Dysfunction.
Rapid detection and identification of counterfeit of adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe.
Rapid Screening and Quantitative Determination of Illegal Phosphodiesterase Type 5 Inhibitors (PDE-5i) in Herbal Dietary Supplements.
Re: A Cost-Utility Analysis of Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction.
Re: comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711.
Re: Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study.
Re: JinQiu Yuan, RenJie Zhang, ZuYao Yang, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902-12.
Re: Panagiotis Kallidonis, Constantinos Adamou, Dimitrios Kotsiris, et al. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. Eur Urol Focus 2020;6:537-58.
Re: Placebo Responses among Men with Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-Analysis.
Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Re: zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors.
Real-World Assessment of the Impact of Erectile Dysfunction on Sexual Planning Behavior and Health- and Treatment-Related Outcomes Among Men in 8 Countries.
Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients.
Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students.
Recurrent uveitis due to sildenafil usage in a patient with Behçet's disease.
Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction.
Regional cerebral blood flow following single-dose and continuous-dose tadalafil after stroke.
Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil.
Relaxant effect and possible mechanism of 17-nor-subincanadine E in rabbit corpora cavernosa.
Relaxation of rabbit corpus cavernosum smooth muscle and aortic vascular endothelium induced by new nitric oxide donor substances of the nitrosyl-ruthenium complex.
Reno-protective effects of Phosphodiesterase 5 inhibitors.
Renoprotective Effects of Sildenafil in DOCA-Salt Hypertensive Rats.
Reply to 'Efficacy and safety of phosphodiesterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis'.
Reply to Francesco Montorsi, Eugenio Ventimiglia, and Andrea Salonia's Letter to the Editor re: Panagiotis Kallidonis, Constantinos Adamou, Dimitrios Kotsiris, et al. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. Eur Urol Focus 2020;6:537-58.
Reply to Letter to the Editor: Zotarolimus-Eluting Peripheral Stents for the Treatment of Erectile Dysfunction in Subjects with Suboptimal Response to Phosphodiesterase-5 Inhibitors.
Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
Research in pharmacotherapy for erectile dysfunction.
Restoration of satisfying sex for a castrated cancer patient with complete impotence: a case study.
Resveratrol Stimulates Hydrogen Sulfide (H2 S) Formation to Relax Murine Corpus Cavernosum.
Reversible bilateral subfoveal ellipsoid zone focal thickening associated with overdose of phosphodiesterase type 5 inhibitors intake.
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
Rewarding properties of sildenafil citrate in mice: role of the nitric oxide-cyclic GMP pathway.
Risk of erectile dysfunction associated with use of 5-? reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.
Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Robot-assisted radical prostatectomy in the setting of previous abdominal surgery: Perioperative results, oncological and functional outcomes, and complications in a single surgeon's series.
Robotic radical prostatectomy in 93 cases: Outcomes of the first ERUS robotic urology curriculum trained surgeon in Turkey.
Role of Hydrogen Sulfide in the Physiology of Penile Erection.
Role of sildenafil in neurological disorders.
Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors.
Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction.
Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan.
Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives.
Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial.
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine.
Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil.
Salivary 8-OHdG: a useful biomarker for predicting severe ED and hypogonadism.
Salvage therapy trial for erectile dysfunction using phosphodiesterase type 5 inhibitors and vitamin E: preliminary report.
Scaffoldless tissue engineering of stem cell derived cavernous tissue for treatment of erectile function.
Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: Analytical techniques and challenges.
Screening sexual performance enhancing compounds and their analogues in counterfeit and illicit erectile dysfunction drugs by high-performance liquid chromatography and liquid chromatography-tandem mass spectrometry.
Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction.
Selective Serotonin Reuptake Inhibitors Plus Phosphodiesterase-5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis.
Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability.
Separate or Combined Treatments with Daily Sildenafil, Molsidomine, or Muscle-Derived Stem Cells Prevent Erectile Dysfunction in a Rat Model of Cavernosal Nerve Damage.
Serum homocysteine levels and sildenafil 50 mg response in young-adult male patients without vascular risk factors.
Sexual activity in normal married couples in Japan: Investigation by questionnaire.
Sexual dysfunction after radical prostatectomy: treatment failure or treatment delay?
Sexual dysfunction and infertility in the male spina bifida patient.
Sexual dysfunction in medical practice.
Sexual dysfunction in men with type 2 diabetes.
Sexual life of Japanese patients with erectile dysfunction taking phosphodiesterase type 5 inhibitors: An Internet survey using the Psychological and Interpersonal Relationship Scales-Short Form questionnaire.
Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men.
Sexually transmitted infection in HIV-positive men with erectile dysfunction using phosphodiesterase-5 inhibitors.
Should Low-intensity Extracorporeal Shockwave Therapy Be the First-line Erectile Dysfunction Treatment for Nonresponders to Phosphodiesterase Type 5 Inhibition?
Side effects of using nitrates to treat angina.
Sildenafil (Viagra) and ophthalmology.
Sildenafil (Viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition.
Sildenafil (viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device.
Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.
Sildenafil accelerates liver regeneration after partial hepatectomy in rats.
Sildenafil Acutely Decreases Visual Responses in ON and OFF Retinal Ganglion Cells.
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity.
Sildenafil augments fetal weight and placental adiponectin in gestational testosterone-induced glucose intolerant rats.
Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients.
Sildenafil can induce the onset of a cluster headache bout.
Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness.
Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
Sildenafil citrate does not affect cardiac contractility in human or dog heart.
Sildenafil citrate monohydrate-cyclodextrin nanosuspension complexes for use in metered-dose inhalers.
Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina.
Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.
Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress.
Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.
Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Sildenafil in erectile dysfunction: a critical review.
Sildenafil in ophthalmology: An update.
Sildenafil inhibits the up-regulation of phosphodiesterase type 5 elicited with nicotine and tumour necrosis factor-alpha in cavernosal vascular smooth muscle cells: mediation by superoxide.
Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
Sildenafil or vardenafil nonresponders' erectile response to tadalafil.
Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single-centre open-label uncontrolled trial.
Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth.
Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis.
Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study.
Sildenafil restores endothelial function in the apolipoprotein E knockout mouse.
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
Sildenafil's impact on male infertility: what has changed in 20 years?
Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro.
Sildenafil-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Case report with review.
Sildenafil-induced vasorelaxation is associated with increases in the phosphorylation of the heat shock-related protein 20 (HSP20).
Sildenafil: efficacy and safety in daily clinical experience.
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.
Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men.
Sonography of the penis/erectile dysfunction.
Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor.
Spotlight on vardenafil in erectile dysfunction.
Structural characterization of sulfoaildenafil, an analog of sildenafil.
Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors.
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction.
Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology.
Sudden sensorineural hearing loss associated with vardenafil.
Survival, Continence and Potency (SCP) recovery after radical retropubic prostatectomy: a long-term combined evaluation of surgical outcomes.
Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial.
Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil.
Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.
Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
Synergistic Effects of ACE Insertion/Deletion and GNB3 C825T Polymorphisms on the Efficacy of PDE-5 Inhibitor in Patients with Pulmonary Hypertension.
Synergistic Effects of BAY 60-4552 and Vardenafil on Relaxation of Corpus Cavernosum Tissue of Patients with Erectile Dysfunction and Clinical Phosphodiesterase Type 5 Inhibitor Failure.
Synthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile dysfunction.
Synthesis and Structure Revision of Dimeric Tadalafil Analogue Adulterants in Dietary Supplements.
Systematic Review and Meta-Analysis of the Use of Phosphodiesterase Type 5 Inhibitors for Treatment of Erectile Dysfunction following Bilateral Nerve-Sparing Radical Prostatectomy.
Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
Systemic and metabolic effects of PDE5-inhibitor drugs.
T-type (alpha1G) low voltage-activated calcium channel interactions with nitric oxide-cyclic guanosine monophosphate pathway and regulation of calcium homeostasis in human cavernosal cells.
Tadalafil - a therapeutic option in the management of BPH-LUTS.
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Tadalafil alleviates cisplatin-induced reproductive toxicity through the activation of the Nrf2/HO-1 pathway and the inhibition of oxidative stress and apoptosis in male rats.
Tadalafil as an in vitro sperm motility stimulant.
Tadalafil enhances working memory, and reduces hippocampal oxidative stress in both young and aged mice.
Tadalafil for benign prostatic hyperplasia.
Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Tadalafil for the treatment of pulmonary arterial hypertension.
Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization.
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.
Tadalafil in the treatment of erectile dysfunction.
Tadalafil Integrates Nitric Oxide-Hydrogen Sulfide Signaling to Inhibit High Glucose-Induced Matrix Protein Synthesis in Podocytes.
Tadalafil Lilly ICOS.
Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model.
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
Tadalafil significantly reduces ischemia reperfusion injury in skin island flaps.
Tadalafil therapy for erectile dysfunction following prostatectomy.
Tadalafil, a Phosphodiesterase-5 Inhibitor, Improves Erectile Dysfunction in Patients With Liver Cirrhosis.
Tadalafil-loaded nanostructured lipid carriers using permeation enhancers.
Tadalafil.
Tadalafil: a new agent for erectile dysfunction.
Tadalafil: A Phosphodiesterase-5 Inhibitor for Benign Prostatic Hyperplasia.
Tadalafil: new preparation. Slightly more convenient, but poorly assessed in organic disorders.
Ten Years of Phosphodiesterase Type 5 Inhibitors in Spinal Cord Injured Patients.
Ten-Year Follow-Up of Sildenafil Use in Spinal Cord-Injured Patients with Erectile Dysfunction.
TESTOSTERONE DEFICIT SYNDROME AND ERECTILE DYSFUNCTION.
Testosterone Replacement Therapy: Should It Be Performed in Erectile Dysfunction?
Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease.
Testosterone therapy improves erectile function and libido in hypogonadal men.
Testosterone therapy in erectile dysfunction and hypogonadism.
Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone.
The application of color Doppler flow imaging in the diagnosis and therapeutic effect evaluation of erectile dysfunction.
The application of quantitative methods for identifying and exploring the presence of bias in systematic reviews: PDE-5 inhibitors for erectile dysfunction.
The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
The Association Between Phosphodiesterase-5 Inhibitors and Colorectal Cancer in a National Cohort of Patients.
The cardiovascular safety of tadalafil.
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval.
The daily intake of Tadalafil 5 mg improves the symptoms of chronic anal fissure.
The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.
The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects.
The effect of antihypertensive drugs on erectile function: a proposed management algorithm.
The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.
The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury.
The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review.
The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial.
The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men.
The effect of vardenafil on endothelial function of brachial and cavernous arteries.
The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.
The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanism.
The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction.
The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction.
The efficacy and safety of on-demand Elonza; a generic product of sildenafil in Thai men with erectile dysfunction.
The efficacy and safety of tadalafil: an update.
The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction.
The efficacy and safety of vardenafil in East Asian men with erectile dysfunction.
The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial.
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
The HelpED Study: Agreement and Impact of the Erection Hardness Score on Sexual Function and Psychosocial Outcomes in Men with Erectile Dysfunction and Their Partners.
The impact of sildenafil on molecular science and sexual health.
The Management of Erectile Dysfunction with Placebo Only: Does it Work?
The management of erectile dysfunction: innovations and future perspectives.
The management of phosphodiesterase-5 (PDE5) inhibitor failure.
The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
The Old Made New: Natural Compounds against Erectile Dysfunction.
The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease.
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
The Potential Role of Sildenafil in Cancer Management through EPR Augmentation.
The promise of inhibition of smooth muscle tone as a treatment for erectile dysfunction: where are we now?
The relationship between erectile dysfunction and cardiovascular disease. Part I: pathophysiology and mechanisms.
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors.
The Role of Initial Success Rates and Other Factors in Determining Reliability of Outcomes of Phosphodiesterase Inhibitor Therapy for Erectile Dysfunction: A Pooled Analysis of 17 Placebo-Controlled Trials of Tadalafil for Use as Needed.
The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
The role of nitric oxide in erectile dysfunction: implications for medical therapy.
The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer.
The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
The role of serum testosterone testing: routine hormone analysis is an essential part of the initial screening of men with erectile dysfunction.
The role of statins in erectile dysfunction.
The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
The Selectivity and Potency of the New PDE5 Inhibitor TPN729MA.
The start of pharmacological activity after sublingual administration of sildenafil citrate in 30 patients affected by erectile dysfunction.
The therapeutic dilemma: how to use tadalafil.
The use of phosphodiesterase 5 inhibitors with concomitant medications.
The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
Thinking About Pathomechanisms and Current Treatment of Erectile Dysfunction-"The Stanley Beamish Problem." Review, Recommendations, and Proposals.
Three important components in the regeneration of the cavernous nerve: brain-derived neurotrophic factor, vascular endothelial growth factor and the JAK/STAT signaling pathway.
Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding likely to affect protein's function.
Time of onset of vardenafil orodispersible tablet in a real-life setting - looking beyond randomized clinical trials.
Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil.
Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
Topically applied NO-releasing nanoparticles can increase intracorporal pressure and elicit spontaneous erections in a rat model of radical prostatectomy.
Topically delivered nitric oxide acts synergistically with an orally administered PDE5 inhibitor in eliciting an erectile response in a rat model of radical prostatectomy.
Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.
Toxicological evaluation of a dietary supplement formulated for male sexual health prior to market release.
Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
Transient Rise of Serum Testosterone Level after Single Sildenafil Treatment of Adult Male Rats.
Treating Erectile Dysfunction and Central Neurological Diseases with Oral Phosphodiesterase Type 5 Inhibitors. Review of the Literature.
Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy.
Treatment of dysautonomia associated with Parkinson's disease.
Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.
Treatment of infertility in men with spinal cord injury.
Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.
Treatment Options for Urogenital Dysfunction in Parkinson's Disease.
Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations.
Treatment Satisfaction of Men and Partners Following Switch from On-Demand Phosphodiesterase Type 5 Inhibitor Therapy to Tadalafil 5?mg Once Daily.
Treatment Strategy for Non-Responders to PDE5 Inhibitors.
Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.
Treatments for erectile dysfunction in spinal cord lesioned patients. Are there alternatives to phosphodiesterase type 5 inhibitors?
Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study.
Treatments for erectile dysfunction in spinal cord patients: Alternatives to phosphodiesterase type 5 inhibitors? A review study.
Twelve-Month Efficacy and Safety of Low-Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors.
Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease.
Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction.
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Type 5 phosphodiesterase inhibitors: curing erectile dysfunction.
UHPLC for quality evaluation of genuine and illegal medicines containing sildenafil citrate and tadalafil.
Undiagnosed prediabetes status is associated with a reduced effectiveness of phosphodiesterase type 5 inhibitors in men with erectile dysfunction.
Up-titration of vardena fi l dose from 10 mg to 20 mg improved erectile function in men with spinal cord injury.
Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Ups and downs of Viagra: revisiting ototoxicity in the mouse model.
Urethral diverticulum after endoscopic urethrotomy: case report.
Urinary and sexual manifestations of patients infected by HTLV-I.
Urological aspects of HIV and AIDS.
Urologist practice patterns in the management of premature ejaculation: a nationwide survey.
Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples.
Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy.
Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings.
Use of phosphodiesterase-5 inhibitors by college students.
Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Utilization and prescription patterns of phosphidiesterase-5 inhibitor medications in the United States military health system.
Vacuum therapy in erectile dysfunction-science and clinical evidence.
Validated UPLC-MS/MS assay for the determination of synthetic phosphodiesterase type-5 inhibitors in postmortem blood samples.
Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction.
Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings.
Vardenafil can Improve Continence Recovery after Bilateral Nerve Sparing Prostatectomy: Results of a Randomized, Double Blind, Placebo-Controlled Pilot Study.
Vardenafil improved erectile function in a "real-life" broad population study of men with moderate to severe erectile dysfunction in Australia and New Zealand.
Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification.
Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction.
Vardenafil in men with stable statin therapy and dyslipidemia.
Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.
Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG.
Vardenafil restores erectile function to normal range in men with erectile dysfunction.
Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study.
Vardenafil.
Vardenafil: a new approach to the treatment of erectile dysfunction.
Vardenafil: a new oral treatment for erectile dysfunction.
Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction.
Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.
Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction.
Vascular regenerative therapies for the treatment of erectile dysfunction: current approaches.
Versatile effects of sildenafil: recent pharmacological applications.
Viagra (sildenafil citrate) and ophthalmology.
Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.
Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.
Visual Side Effects Linked to Sildenafil Consumption: An Update.
Words of wisdom. Re: The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. Paick J-S, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh J-K, Kim SC.
Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors.
[Aildenafil citrate: a new potent and highly selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction]
[AN EVIDENCE BASED UPDATE ON THE INVESTIGATION AND MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS].
[Application of the vacuum erectile device in penile rehabilitation for erectile dysfunction after radical prostatectomy].
[Avanafil for the treatment of erectile dysfunction in practice. Non-interventional study AVANTI].
[Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption]
[Chronic PDE-5 inhibition in patients with erectile dysfunction : New treatment approach using once daily Tadalafil.]
[Combination of 1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction: results of observatory prospective multicenter study].
[Combination therapy in benign prostatic hyperplasia (BPH)]
[Combined treatment of patients with erectile dysfunction and urination disorders].
[Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction]
[Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities].
[Current role of sildenafil in the management of erectile dysfunction].
[Dosage forms of sildenafil in the management of erectile dysfunction].
[ED patients and their female partners prefer tadalafil].
[Efficacy and safety of phosphodiesterase inhibitors for erectile dysfunction in diabetic men: A meta analysis].
[Efficacy and safety of tadalafil for erectile dysfunction: an updated review]
[Efficacy and safety of vardenadil in difficult-to-treat erectile dysfunction men]
[Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction].
[Erectile dysfunction and incontinence after prostatectomy. Treating the complications of surgery for prostate cancer].
[Erectile dysfunction and phosphodiesterase type 5 inhibitors]
[Evaluation of tadalafil for the treatment of erectile dysfunction]
[Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction]
[Features of subjects purchasing Sildenafil at community pharmacies in Concepción, Chile]
[Good sex inspite of erectile dysfunction. A new PDE-5 inhibitor gives more latitude]
[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
[Hydrogen sulfide and penile erection].
[Identification of Descarbonsildenafil in an Adulterated Dietary Supplement and Evaluation of Its Inhibitory Activity for Phosphodiesterase Type 5 (PDE5)].
[Impact of rAd5-shRNA- PDE5A3 on cGMP in the smooth muscle cells of human corpus cavernosum]
[Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval]
[Levitra (wardenafil) effects on endothelial function of brachial and cavernous arteries]
[Long-term administration of low-dose phosphodiesterase type 5 inhibitors for erectile dysfunction: an update].
[Low-dose tadalafil improves arterial erectile dysfunction]
[Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
[Medicinal therapy of benign prostate syndrome].
[Modernity in the treatment of erectile dysfunction: Levitra (vardenafil) in the form of oral dispersible tablet].
[New application of phosphodiesterase-5 inhibitors in uro-andrology].
[New data on the effectiveness of Tadalafil alone and in combination with NeyroDoz in treating erectile dysfunction associated with secondary premature ejaculation].
[New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again]
[New treatment strategies for male lower urinary tract symptoms].
[Patient with testosterone deficit syndrome and erectile dysfunction non-responder to PDE-5 inhibitors].
[PDE5 inhibitors as a medicinal guide drug in the treatment of erectile dysfunction].
[PDE5 inhibitors for the management of temporary penile erectile dysfunction during treatment with assisted reproductive technology].
[Pharmacological treatment of benign prostatic hyperplasia].
[Pharmacological treatment of BPS].
[Phosphodiesterase 5 inhibition in erectile dysfunction. Long-term administration without therapeutic advantage]
[Phosphodiesterase inhibitors are effective in treating erectile dysfunction in diabetic men]
[Phosphodiesterase inhibitors in clinical practice. The present and the future. Part I]
[Phosphodiesterase inhibitors: effectiveness and new applications]
[Phosphodiesterase type 5 inhibitors for premature ejaculation: advances in studies].
[Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
[Phosphodiesterase type 5 siRNA increases cGMP in the smooth muscle cells of human corpus cavernosum]
[Phosphodiesterase-5 inhibitors for erectile dysfunction: Adverse reactions and countermeasures].
[Safety of tadalafil in patients with cardiovascular comorbidities].
[Sexual activity and cardiovascular risk]
[Sexuality in the elderly : The role of the physicians in maintaining sexual health of older men].
[Should we recommend an erectile rehabilitation after radical prostatectomy? Systematic review of the literature by the Sexual Medicine Committee of the French Urology Association].
[Sildenafil assumption and acute effects on the uroflowmetric parameters.]
[Sildenafil]
[Single base polymorphisms and erectile dysfunction.]
[Tadalafil for erectile dysfunction: efficacy evaluation]
[Tadalafil for erectile dysfunction: excellent safety and tolerance]
[Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]
[Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].
[The effects of sildenafil citrate on the isolated rat aorta: comparative in vitro study]
[The treatments of localized prostate cancer: the impact on sexuality]
[Therapeutic effect of phosphodiesterase-5 inhibitor on pathological changes of tunica albuginea in erectile dysfunction: experiment with rats]
[Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction]
[Therapy for organic erectile dysfunction]
[Therapy of erectile dysfunction. New, highly selective PDE-5 inhibitor]
[Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)]
[TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING TRANSVESICAL PROSTATECTOMY].
[Treatment of erectile dysfunction with PDE-5 inhibitors. Difficult for the physician to choose between the preparations--the patient should be given the opportunity to try out all three]
[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]
[Update of PDE5 inhibitors for the treatment of ischemia-reperfusion].
[Urinary and sexual disorders following localised prostate cancer management].
[Viagra, cialis, impase--which of them, to whom, when and how?]
[Whole rehabilitation: a new goal of erectile dysfunction therapy]
Escherichia coli Infections
Phosphodiesterase 5 (PDE5) restricts intracellular cGMP accumulation during enterotoxigenic Escherichia coli infection.
Esophageal Achalasia
Effect of sildenafil, a phosphodiesterase-5 inhibitor, on oesophageal peristalsis and lower oesophageal sphincter function in cats.
Treatment of esophageal motility disorders based on the chicago classification.
Essential Hypertension
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Chronic sildenafil treatment corrects endothelial dysfunction and improves hypertension.
ERECTILE DYSFUNCTION AS A PREDICTOR OF CARDIOVASCULAR DISEASE.
Phosphodiesterase 5 inhibition in essential hypertension.
Phosphodiesterase 5 inhibition to treat essential hypertension: is this the beginning of the story?
Eye Diseases
Generalized progressive retinal atrophy of Sloughi dogs is due to an 8-bp insertion in exon 21 of the PDE6B gene.
Retinal imaging in inherited retinal diseases.
Familial Primary Pulmonary Hypertension
Conservative management of an elderly patient with Eisenmenger syndrome.
Dual therapy in IPAH and SSc-PAH. A qualitative systematic review.
Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.
Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement.
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.
Hepatopulmonary syndrome and portopulmonary hypertension: what's new?
Iloprost for idiopathic pulmonary arterial hypertension.
Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.
Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets.
Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease.
Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects.
Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.
Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro.
The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial.
Treatment of primary pulmonary hypertension with oral sildenafil.
[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]
[Cardio-vascular effects of sildenafil: new data]
[Treatment of pulmonary hypertension]
Fetal Growth Retardation
Early-onset fetal growth restriction treated with the long-acting phosphodiesterase-5 inhibitor tadalafil: a case report.
Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Tadalafil alleviates preeclampsia and fetal growth restriction in RUPP model of preeclampsia in mice.
Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice.
The effects of sildenafil citrate (Viagra) on uterine blood flow and well being in the intrauterine growth-restricted fetus.
The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction.
Fetal Hypoxia
Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double-blind randomised control trial.
Fissure in Ano
Manometric study of topical sildenafil (Viagra) in patients with chronic anal fissure: sildenafil reduces anal resting tone.
Gastroesophageal Reflux
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology.
Glaucoma
Identification of PDE6D as a Molecular Target of Anecortave Acetate via a Methotrexate-Anchored Yeast Three-Hybrid Screen.
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Urologic medications and ophthalmologic side effects: a review.
Glioblastoma
Characterization of inhibitors of phosphodiesterase 1C on a human cellular system.
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Glioma
Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma.
Glomerulonephritis
PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.
Phosphodiesterase-5 gene (PDE5A) polymorphisms are associated with progression of childhood IgA nephropathy.
Glomerulonephritis, IGA
Phosphodiesterase-5 gene (PDE5A) polymorphisms are associated with progression of childhood IgA nephropathy.
Glucose Metabolism Disorders
Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue.
Gyrate Atrophy
Retinal imaging in inherited retinal diseases.
Head and Neck Neoplasms
Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.
Hearing Loss
A Natural Occurring Mouse Model with Adgrv1 Mutation of Usher Syndrome 2C and Characterization of its Recombinant Inbred Strains.
Comprehensive Molecular Screening in Chinese Usher Syndrome Patients.
Drug-induced hearing loss.
Hearing loss with phosphodiesterase-5 inhibitors: a prospective and objective analysis with tadalafil.
Histopathologic results of long-term sildenafil administration on rat inner ear.
Phosphodiesterase type 5 inhibitor use and hearing impairment.
Sudden sensorineural hearing loss associated with vardenafil.
Viagra deafness--sensorineural hearing loss and phosphodiesterase-5 inhibitors.
Hearing Loss, Noise-Induced
Therapeutic effect of sildenafil on blast-induced tinnitus and auditory impairment.
Hearing Loss, Sensorineural
Phosphodiesterase type 5 inhibitors and sudden sensorineural hearing loss.
Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population-based cohort study.
Sudden hearing loss after cialis (tadalafil) use: A unique case of cochlear hydrops.
Sudden sensorineural hearing loss associated with vardenafil.
Hearing Loss, Sudden
Effect of phosphodiesterase-5 inhibitor on hearing.
Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology.
Heart Arrest
Sildenafil after cardiac arrest and infarction; an experimental rat model.
The protective effects of phosphodiesterase-5 inhibitor, sildenafil on post-resuscitation cardiac dysfunction of cardiac arrest: by regulating the miR-155-5p and miR-145-5p.
The protective effects of phosphodiesterase-5 inhibitor, sildenafil on post-resuscitation cardiac dysfunction of cardiac arrest: metabolic evidence from microdialysis.
Heart Defects, Congenital
Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design.
Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Heart Diseases
An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.
Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging.
Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Is there a relationship between sex hormones and erectile dysfunction? Results from the Massachusetts Male Aging Study.
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro.
Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.
Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients.
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review.
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
[The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease]
Heart Failure
Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure.
An MRTF-A-Sp1-PDE5 Axis Mediates Angiotensin-II-Induced Cardiomyocyte Hypertrophy.
Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction.
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.
Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure.
Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function.
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure.
Chronic Inhibition of Cyclic Guanosine Monophosphate-Specific Phosphodiesterase 5 Suppresses Endoplasmic Reticulum Stress in Heart Failure.
Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction.
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure.
Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems.
Differential effects of phosphodiesterase-5 inhibition in chronic cardiac decompensation, depending on the type, whether HFREF or HFpEF, of heart failure: a meta-analysis.
Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling.
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Endothelin-1 and peak oxygen consumption in patients with heart failure with preserved ejection fraction.
Enhancement of Myocardial and Vascular Function after Phosphodiesterase-5 Inhibition in a Rat Model.
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.
Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5).
Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
Improved erectile function after cardiac resynchronization therapy in a patient with heart failure-a case report.
Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure.
Letter by Cingolani et al regarding article, "Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice".
Letter by forfia and borlaug regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Letter by gordon et Al regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Letter by Hutchings et al Regarding Article, "Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation : An INTERMACS Analysis".
Letter by jamous regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway.
Long-term use of sildenafil in the therapeutic management of heart failure.
MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A.
Mitigation of the Progression of Heart Failure with Sildenafil Involves Inhibition of RhoA/Rho-Kinase Pathway.
Non erectile dysfunction application of sildenafil.
Novel phosphodiesterase-5 inhibitors: Current indications and future directions.
Oral sildenafil: Potential role in heart transplantation. Review of the literature and personal experience.
Oxidative stress regulates left ventricular PDE5 expression in the failing heart.
PDE5 inhibitor efficacy is estrogen dependent in female heart disease.
Phosphodiesterase 5 Associates With ?2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts.
Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure.
Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications.
Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G I? Oxidation.
Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure.
Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory Cytokines.
Phosphodiesterase 9 Inhibition in Models of Heart Failure With Preserved Left Ventricular Ejection Fraction: Should We Focus on the Positive or Negative?
Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men.
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention.
Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.
Phosphodiesterase-5 inhibitors: future perspectives.
Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro.
Phosphodiesterases and cardiac cGMP: evolving roles and controversies.
Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure.
Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation.
Prevention of Right Heart Failure After Left Ventricular Assist Device Implantation by Phosphodiesterase 5 Inhibitor.
Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.
Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.
Response by Blanton et al to Letter Regarding Article, "Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After LVAD Implantation: An INTERMACS Analysis".
RETRACTION NOTE TO: Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Right heart failure after left ventricular assist device implantation: early and late.
Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.
S-nitrosylation of PDE5 increases its ubiquitin-proteasomal degradation.
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model.
Sildenafil and assessment of pulmonary arterial reactivity in heart failure.
Sildenafil and Cardioprotection.
Sildenafil and phosphodiesterase-5 inhibitors for heart failure.
Sildenafil citrate (Viagra) enhances vasodilatation by atrial natriuretic peptide in normal dogs.
Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.
Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.
Sustained improvement of clinical status and pulmonary hypertension in patients with severe heart failure treated with sildenafil.
T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters.
Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review.
Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.
The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure.
The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: A case-control study.
The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
The emerging role for type 5 phosphodiesterase inhibitionin heart failure.
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Type 5 phosphodiesterase inhibition in heart failure: the next step.
Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil.
Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
[Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients?].
Heart Failure, Diastolic
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction.
Identifying a low-flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial.
Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.
Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
Heart Failure, Systolic
Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.
Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation.
Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure.
Heart Rupture
Phosphodiesterase-5a Knock-out Suppresses Inflammation by Down-Regulating Adhesion Molecules in Cardiac Rupture Following Myocardial Infarction.
Heart Valve Diseases
Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease.
Hemangioma
Sildenafil suppresses the proliferation and enhances the apoptosis of hemangioma endothelial cells.
Hematologic Diseases
Independent Predictive Factors for Occurrence of Ischemic Priapism after Papaverine Injection.
Hernias, Diaphragmatic, Congenital
Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia.
Dypiridamole, a cGMP phosphodiesterase inhibitor, transiently improves the response to inhaled nitric oxide in two newborns with congenital diaphragmatic hernia.
HIV Infections
High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
HIV Seropositivity
The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention.
Hodgkin Disease
Cyclic AMP and cyclic GMP phosphodiesterase activities in Hodgkin's disease lymphocytes.
t(4;8)(q27;q24) in Hodgkin lymphoma cells targets phosphodiesterase PDE5A and homeobox gene ZHX2.
Huntington Disease
Chromosome mapping of the rod photoreceptor cGMP phosphodiesterase beta-subunit gene in mouse and human: tight linkage to the Huntington disease region (4p16.3).
Exclusion of DNA changes in the beta-subunit of the c-GMP phosphodiesterase gene as the cause for Huntington's disease.
Genomic organization and complete sequence of the human gene encoding the beta-subunit of the cGMP phosphodiesterase and its localisation to 4p 16.3.
Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF.
Hyperalgesia
Characterization of a novel model of chronic migraine.
Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy.
NO/cGMP production is important for the endogenous peripheral control of hyperalgesia during inflammation.
Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil.
The kappa-opioid agonist (+/-)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway.
Hypercholesterolemia
The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
Hyperemia
Phosphodiesterase-5 Inhibitor Use: An Under-reported Cause of Profuse Nasal Bleeding.
Potentiation of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans.
Hyperglycemia
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Cinaciguat in combination with insulin induces a favorable effect on implant osseointegration in type 2 diabetic rats.
Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects.
Decreased permeability surface area for glucose in obese women with postprandial hyperglycemia: no effect of phosphodiesterase-5 (PDE-5) inhibition.
Hyperhomocysteinemia
Tadalafil ameliorates memory deficits, oxidative stress, endothelial dysfunction and neuropathological changes in rat model of hyperhomocysteinemia induced vascular dementia.
Hyperlipidemias
Mechanisms underlying dysfunction of carotid arteries in genetically hyperlipidemic rabbits.
Hyperlipoproteinemia Type II
Differential impact of severe familial hypercholesterolemia on regional skeletal muscle and organ blood flows during exercise: Effects of PDE5 inhibition.
Hypersensitivity
Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice.
Hypertension
3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
A case of long-term sildenafil therapy in a young dog with pulmonary hypertension.
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.
A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension.
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.
A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension.
Abnormalities of platelet function in hypertension and diabetes.
Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.
Acute, Bilateral, Concurrent Central Retinal Artery Occlusion in Sickle Cell Disease After Use of Tadalafil (Cialis).
Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
An evidence-based approach to the management of pulmonary arterial hypertension.
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study.
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
Blood Pressure Lowering Effects of a New Long-Acting Inhibitor of Phosphodiesterase 5 in Patients With Mild to Moderate Hypertension.
Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).
Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function.
Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.
Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease.
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Classical activation of macrophages and vardenafil.
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension.
Clinical use of sildenafil in pulmonary artery hypertension.
Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension.
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Comparison of health-related quality-of-life outcomes for African-American and Caucasian-American men after radical prostatectomy.
Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension.
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.
Conservative management of an elderly patient with Eisenmenger syndrome.
Conversion From Sildenafil to Tadalafil: Results From the Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) Study.
Current diagnosis and management of erectile dysfunction.
Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension.
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition.
Development and validation of a GC/MS method for the determination of tadalafil in whole blood.
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification.
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Dual therapy in IPAH and SSc-PAH. A qualitative systematic review.
Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.
Effect of regular phosphodiesterase type 5 inhibition in hypertension.
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.
Effect of sildenafil citrate on brain central fatigue after exhaustive swimming exercise in rats.
Effect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in mice.
Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Effect of treating erectile dysfunction on management of systolic hypertension.
Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Effects of sildenafil on maternal hemodynamics and fetal growth in normal rat pregnancy.
Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.
Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
Efficacy of Oral Tadalafil, a New Long-acting Phosphodiesterase-5 Inhibitor, for the Short-term Treatment of Pulmonary Arterial Hypertension in a Dog.
Emerging therapies for the treatment of pulmonary hypertension.
Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus.
Erectile dysfunction and hypertension.
Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5).
Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Expression of myosin isoforms in the smooth muscle of human corpus cavernosum.
Extracts from Almond (Terminalia catappa) leaf and stem bark mitigate the activities of crucial enzymes and oxidative stress associated with hypertension in cyclosporine A-stressed rats.
Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension.
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.
Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan.
Future treatments in systemic sclerosis.
Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment.
High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.
Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies.
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE.
Iloprost for idiopathic pulmonary arterial hypertension.
Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.
In Silico Investigations of Chemical Constituents of Clerodendrum colebrookianum in the Anti-Hypertensive Drug Targets: ROCK, ACE, and PDE5.
In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil.
Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells.
Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Letter by forfia and borlaug regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Letter by gordon et Al regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Letter by jamous regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan.
Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.
Mechanisms Involved in the Remyelinating Effect of Sildenafil.
Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.
Medical treatment update on pulmonary arterial hypertension.
Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors.
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil.
New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?
New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
Nonaneurysmal Subarachnoid Hemorrhage after Udenafil Intake.
Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.
Novel phosphodiesterase-5 inhibitors: Current indications and future directions.
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.
One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease.
Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension.
Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): A Randomized Controlled Trial.
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study): A Randomized Controlled Trial.
PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.
Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report.
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.
Phosphodiesterase 5 inhibition ameliorates angiotensin II-dependent hypertension and renal vascular dysfunction.
Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension.
Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report.
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Phosphodiesterase type 5 and high altitude pulmonary hypertension.
Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.
Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia.
Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.
Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension.
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study.
Portopulmonary hypertension and right heart failure in patients with cirrhosis.
Potential Therapeutic Role of Phosphodiesterase Type 5 Inhibition in Hypertension and Chronic Kidney Disease.
Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis.
Preparation of sildenafil citrate microcapsules and in vitro/in vivo evaluation of taste masking efficiency.
Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.
Pulmonary arterial hypertension.
Pulmonary Hypertension and HIV infection: epidemiology, pathogenesis, and clinical approach.
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.
Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets.
Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.
Pulmonary hypertension in systemic lupus erythematosus.
Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Recent advances in the treatment of systemic sclerosis.
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.
Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
Reverse-phase high-performance liquid chromatography for the simultaneous determination of sildenafil and N-desmethyl sildenafil in plasma of children.
Review of inhaled iloprost for the control of pulmonary artery hypertension in children.
RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity.
Right ventricular failure: a novel era of targeted therapy.
Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension.
Safety and Efficacy of Ambrisentan-Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice.
Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives.
Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension.
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Selexipag: A Review in Pulmonary Arterial Hypertension.
Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.
Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
Sildenafil for pulmonary arterial hypertension.
Sildenafil for Pulmonary Arterial Hypertension.
Sildenafil for pulmonary arterial hypertension: when blue turns into white.
Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.
Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension.
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects.
Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
Sildenafil: a review of its use in pulmonary arterial hypertension.
Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension.
Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension.
Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.
Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors.
Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report.
Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology.
Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors.
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes.
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Tadalafil for benign prostatic hyperplasia.
Tadalafil for the treatment of pulmonary arterial hypertension.
Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.
Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro.
Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment.
Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Tadalafil: in pulmonary arterial hypertension.
The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis.
The hypertensive effect of sorafenib is abolished by sildenafil.
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
The molecular targets of approved treatments for pulmonary arterial hypertension.
The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease.
The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells.
Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations.
Treatment Algorithms for Systemic Sclerosis According to Experts.
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.
ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.
Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia.
Vacuum Erection Devices Revisited: Its Emerging Role in the Treatment of Erectile Dysfunction and Early Penile Rehabilitation Following Prostate Cancer Therapy.
Vacuum erection devices to treat erectile dysfunction and early penile rehabilitation following radical prostatectomy.
Vardenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study.
Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
[Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension.]
[Correlation between hypertension and erectile dysfunction].
[Diagnosis and treatment of pulmonary hypertension].
[Drug-induced sexual dysfunction].
[Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension].
[Emerging Therapies for the Treatment of Pulmonary Arterial Hypertension.]
[Future aspects of the treatment of pulmonary arterial hypertension.]
[Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension]
[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension]
[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
[Pulmonary arterial hypertension]
[The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease]
[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors]
Hypertension, Portal
Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. A novel therapeutic option for portal hypertension.
Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.
Haemodynamic and renal effects of tadalafil in patients with cirrhosis.
Hepatopulmonary syndrome and portopulmonary hypertension: what's new?
Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Hypertension, Pulmonary
A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine.
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology.
A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors.
Acute and chronic effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats.
Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.
Acute pulmonary hypertension in infants and children: cGMP-related drugs.
Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension.
Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.
Additive Effect of Tadalafil and Simvastatin on monocrotaline-induced pulmonary hypertension rats.
An Accidental Repetitive 10-Fold Overdose of Sildenafil in a Young Infant with Pulmonary Hypertension.
An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-activated protein kinase pathway in animal and cellular models of pulmonary hypertension.
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
Cardioprotection with sildenafil: implications for clinical practice.
Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity.
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.
Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion.
Clinical trials in group 3 pulmonary hypertension.
Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension.
Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.
Comparative single-dose pharmacokinetics of sildenafil after oral and rectal administration in healthy beagle dogs.
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses.
Current Concepts in Management of Pulmonary Hypertension: Fighting the Old Demon with Modern Weapons.
Current practices in the use of sildenafil for pulmonary arterial hypertension in Brazilian hospitals.
DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension.
DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats.
Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood.
Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema.
Differential expression of PDE5 in failing and nonfailing human myocardium.
Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure.
Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.
Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets.
Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.
E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats.
Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction.
Effect of a Phosphodiesterase 5 Inhibitor on Pulmonary and Cerebral Arteries of Newborn Piglets with Chronic Hypoxia-Induced Pulmonary Hypertension.
Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats.
Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.
Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery.
Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Effects and mechanisms of action of sildenafil citrate in human chorionic arteries.
Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome.
Effects of sildenafil on pentylenetetrazol-induced convulsions in mice and amygdala-kindled seizures in rats.
Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection.
Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos.
Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.
Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015.
Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice.
Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
Hemodynamic and Gas Exchange Effects of Sildenafil in Patients with COPD and Pulmonary Hypertension.
Hydrocortisone normalizes phosphodiesterase-5 activity in pulmonary artery smooth muscle cells from lambs with persistent pulmonary hypertension of the newborn.
Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia.
Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide.
Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil.
Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats.
Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Inhibition of cGMP phosphodiesterase 5 suppresses MMP2 production in pulmonary artery smooth muscles cells.
Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells.
Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling.
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension.
Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome.
Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets.
Intravenous tezosentan and vardenafil attenuate acute hypoxic pulmonary hypertension.
L-Arginine in combination with sildenafil potentiates the attenuation of hypoxic pulmonary hypertension in rats.
Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats.
Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats.
Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension.
Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease.
Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway.
Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension.
Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.
Meta-analysis of clinical efficacy of sildenafil, a phosphodiesterase type-5 inhibitor on high altitude hypoxia and its complications.
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor.
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.
Ocular findings of oral sildenafil use in term and near-term neonates.
Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation.
Oxytocinergic system mediates the proconvulsant effects of sildenafil: The role of calcineurin.
PDE-5 inhibitors: current status and future trends.
PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.
PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.
Persistent pulmonary hypertension in the newborn: therapeutic effect of sildenafil.
Phenanthrenes from Eulophia macrobulbon as Novel Phosphodiesterase-5 Inhibitors.
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
Phoshphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?
Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies.
Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation.
Phosphodiesterase type 5 and high altitude pulmonary hypertension.
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.
Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men.
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.
Phosphodiesterase type 5 inhibitors and kidney disease.
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a meta-analysis.
Phosphodiesterase type 5 inhibitors in pulmonary hypertension: a Hobson's choice for Indian patients.
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia.
Phosphodiesterase-5 Inhibitors and Outcomes During Left Ventricular Assist Device Support: A Systematic Review and Meta-Analysis.
Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.
Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy.
Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period.
Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis.
Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.
Proconvulsant effects of sildenafil citrate on pilocarpine-induced seizures: Involvement of cholinergic, nitrergic and pro-oxidant mechanisms.
Pulmonary arterial hypertension and statins: an update.
Pulmonary hypertension complicating congenital heart disease.
Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
Pulmonary Hypertension Therapy and a Systematic Review of Efficacy and Safety of PDE-5 Inhibitors.
Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors.
Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus.
Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
Recent advances in sarcoidosis.
Reno-protective effects of Phosphodiesterase 5 inhibitors.
Reversal of pulmonary arterial hypertension in POEMS syndrome with thalidomide: a case report.
Right heart failure after left ventricular assist device implantation: early and late.
Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
Selective pulmonary vasodilation induced by aerosolized zaprinast.
Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil.
sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension.
Sildenafil Acutely Decreases Visual Responses in ON and OFF Retinal Ganglion Cells.
Sildenafil and assessment of pulmonary arterial reactivity in heart failure.
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
Sildenafil citrate monohydrate-cyclodextrin nanosuspension complexes for use in metered-dose inhalers.
Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery.
Sildenafil for the treatment of pulmonary hypertension in pediatric patients.
Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension.
Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
Sildenafil in a cigarette smoke-induced model of COPD in the guinea-pig.
Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.
Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling.
Sildenafil in the treatment of pulmonary hypertension.
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.
Simvastatin and sildenafil combine to attenuate pulmonary hypertension.
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial.
Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
Sudden sensorineural hearing loss associated with vardenafil.
SUPEROXIDE DISMUTASE AND INHALED NITRIC OXIDE NORMALIZE PHOSPHODIESTERASE 5 EXPRESSION AND ACTIVITY IN NEONATAL LAMBS WITH PERSISTENT PULMONARY HYPERTENSION.
Supporting the use of sildenafil infusions in paediatric and neonatal intensive care - A compatibility study.
Synergistic Effects of ACE Insertion/Deletion and GNB3 C825T Polymorphisms on the Efficacy of PDE-5 Inhibitor in Patients with Pulmonary Hypertension.
Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension.
Systematic Review of Phosphodiesterase-5 Inhibitor Use in Right Ventricular Failure Following Left Ventricular Assist Device Implantation.
Tadalafil improves oxygenation in a model of newborn pulmonary hypertension.
Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome.
Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.
Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review.
The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation.
The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation.
The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review.
The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: A case-control study.
The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis.
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA).
The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History.
Therapeutic options for digital ulcers in patients with systemic sclerosis.
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Treatment Algorithms in Systemic Lupus Erythematosus.
Treatment of schistosomiasis-associated pulmonary hypertension.
Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Type II Diabetes Patients under Sildenafil Citrate: Case Series Showing Benefits and a Side Effect.
Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.
Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets.
X-linked CD40 ligand deficiency in a 1-year-old male Shih Tzu with secondary Pneumocystis pneumonia.
Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone.
[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]
[E 4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats]
[Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome]
[Medical treatment of pulmonary arterial hypertension.]
[Mountain sickness].
[New treatments of pediatric pulmonary hypertension].
[Recommended guideline for the use of medical therapy in pulmonary hypertension]
[Sildenafil in the treatment of pulmonary hypertension]
[Sildenafil reduces pressure and pulmonary resistance and increases susceptibility of pulmonary arteries to nitric oxide in primary pulmonary arterial hypertension]
[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension].
[Treatment algorithm for pulmonary arterial hypertension.]
[Treatment of pulmonary hypertension associated with connective tissue disease]
Hypertension, Renal
Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy.
Hypertension, Renovascular
Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension.
Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.
Sildenafil Improves Vascular Endothelial Structure and Function in Renovascular Hypertension.
Hyperthyroidism
Changes of calmodulin concentration and cyclic 3',5'-nucleotide phosphodiesterase activities in cardiac muscle of hyper- and hypothyroid rats.
Human thyroid cyclic nucleotide phosphodiesterase. Its characterization and the effect of several hormones on the activity.
Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
Hypertrophy, Right Ventricular
DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension.
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.
Hypogonadism
Aging and sexual health: getting to the problem.
Assessing the Variability in Insurance Coverage Transparency for Male Sexual Health Conditions in the United States.
Clinical efficiency of combination therapy using testosterone replacement therapy, phosphodiesterase 5 inhibitors and Kampo herbal medicine for eugonadal patients with late-onset hypogonadism syndrome.
Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis.
Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction.
Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadism.
Erectile dysfunction in aging male.
Hypogonadism and erectile dysfunction as harbingers of systemic disease.
Testosterone and erectile dysfunction.
TESTOSTERONE DEFICIT SYNDROME AND ERECTILE DYSFUNCTION.
Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes.
The evolving role of testosterone in the treatment of erectile dysfunction.
[Sexuality in overweight and obesity].
Hypotension
An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects.
Effect of pharmacological manipulation of endogenous atriopeptin activity on renal function.
Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis.
Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease.
Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery.
Melanocortins in the treatment of male and female sexual dysfunction.
Oral sildenafil increases skin hyperaemia induced by iontophoresis of sodium nitroprusside in healthy volunteers.
PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH PHOSPHODIESTERASE-5 INHIBITOR THERAPY.
Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate.
Sexual function in hypertensive patients receiving treatment.
Side effects of using nitrates to treat angina.
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Sildenafil Increases Sympathetically Mediated Vascular Tone in Humans.
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
The hemodynamic interactions of combination therapy with ?-blockers and phosphodiesterase-5 inhibitors compared to monotherapy with ?-blockers: a systematic review and meta-analysis.
The Safety of Preoperative Vardenafil in Patients Undergoing Coronary Artery Bypass Graft Surgery.
[Cardiovascular disease and sexuality]
Hypotension, Orthostatic
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.
The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Hypothyroidism
Cyclic nucleotide phosphodiesterases, insulin and thyroid hormones.
Idiopathic Pulmonary Fibrosis
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.
MiR-200a inversely correlates with Hedgehog and TGF-? canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model.
Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis.
Infections
Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease.
Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage?
Enhanced recovery from respiratory infection following treatment with a PDE-5 inhibitor: a single case study.
Phosphodiesterase 5 (PDE5) restricts intracellular cGMP accumulation during enterotoxigenic Escherichia coli infection.
Schistosomiasis and the pulmonary vasculature (2013 Grover Conference series).
Seminal vesicles of infertile patients with male accessory gland infection: ultrasound evaluation after prolonged treatment with tadalafil, a selective phosphodiesterase-5 inhibitor.
Sexually transmitted infection in HIV-positive men with erectile dysfunction using phosphodiesterase-5 inhibitors.
Inferior Wall Myocardial Infarction
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Infertility
Sildenafil's impact on male infertility: what has changed in 20 years?
Infertility, Male
Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis.
Effect of Phosphodiesterase-5 Inhibitors on the Treatment of Male Infertility: A Systematic Review and Meta-Analysis.
Inflammatory Bowel Diseases
Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress.
Insulin Resistance
Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice.
Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects.
Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells.
Interaction between leucine and phosphodiesterase 5 inhibition in modulating insulin sensitivity and lipid metabolism.
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes.
The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function.
Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial.
Type II Diabetes Patients under Sildenafil Citrate: Case Series Showing Benefits and a Side Effect.
Insulinoma
The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion.
Intellectual Disability
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Ischemic Stroke
Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies.
Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial.
Sildenafil improves scotoma after posterior cerebral infarctions: a case report.
Kidney Diseases
Phosphodiesterase type 5 inhibitors and kidney disease.
Kidney Failure, Chronic
Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage.
Phosphodiesterase Type 5 Inhibitor Treatment for Erectile Dysfunction in Patients with End-Stage Renal Disease Receiving Dialysis or After Renal Transplantation.
The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips.
Leber Congenital Amaurosis
AIPL1, the protein that is defective in Leber congenital amaurosis, is essential for the biosynthesis of retinal rod cGMP phosphodiesterase.
Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase.
Retinal imaging in inherited retinal diseases.
Leukemia
Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension.
Leukemia, Myeloid, Acute
Phosphodiesterase 5 inhibitor acts as a potent agent sensitizing acute myeloid leukemia cells to 67-kDa laminin receptor-dependent apoptosis.
Liver Cirrhosis
Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.
Effect of chronic administration of sildenafil on sodium retention and on the hemodynamic complications associated with liver cirrhosis in the rat.
Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis.
Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.
Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat.
Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Tadalafil, a Phosphodiesterase-5 Inhibitor, Improves Erectile Dysfunction in Patients With Liver Cirrhosis.
The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats.
Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
Liver Cirrhosis, Biliary
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Liver Cirrhosis, Experimental
Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Liver Diseases
Anti-Inflammatory Effects of Vardenafil Against Cholestatic Liver Damage in Mice: a Mechanistic Study.
Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study.
Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Liver Failure
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Liver Neoplasms
In vitro perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis.
The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression.
Long QT Syndrome
Phosphodiesterase 5: A Novel Therapeutic Target in Long QT Syndrome.
Lung Diseases
Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
Lung Diseases, Interstitial
Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
Lung Injury
Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury.
Lupus Nephritis
Treatment Algorithms in Systemic Lupus Erythematosus.
Lymphoma
Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model.
Macular Degeneration
Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review.
PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH PHOSPHODIESTERASE-5 INHIBITOR THERAPY.
Retinal imaging in inherited retinal diseases.
Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year Trial.
Macular Edema
Clinical and genetic investigations of three Moroccan families with retinitis pigmentosa phenotypes.
Malaria
PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum.
Topological polar surface area: a useful descriptor in 2D-QSAR.
Meconium Aspiration Syndrome
Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension.
Medulloblastoma
PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.
Melanoma
Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.
cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells.
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Expression and role of phosphodiesterase 5 in human malignant melanoma cell line.
Hard times for oncogenic BRAF-expressing melanoma cells.
Involvement of cGMP in cellular melatonin responses.
Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma.
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.
Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.
Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.
Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects.
Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Photoreceptor proteins as cancer-retina antigens.
Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711.
Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review.
Retraction Note to: cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells.
Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Role of rare germline copy number variation in melanoma-prone patients.
Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth.
Sildenafil Use and Increased Risk of Incident Melanoma in US Men: A Prospective Cohort Study.
Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe).
Targeting invasive properties of melanoma cells.
Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies.
Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Viagra releases the brakes on melanoma growth.
Visible light modulates the expression of cancer-retina antigens.
Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Memory Disorders
Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice.
Moderate treadmill exercise improves spatial learning and memory deficits possibly via changing PDE-5, IL-1 ? and pCREB expression.
Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition.
Metabolic Syndrome
Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.
Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors.
Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.
Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.
Sildenafil citrate long-term treatment effects on cardiovascular reactivity in a SHR experimental model of metabolic syndrome.
Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone.
The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Migraine Disorders
Cerebral haemodynamic response or excitability is not affected by sildenafil.
Characterization of a novel model of chronic migraine.
Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.
Migraine can be induced by sildenafil without changes in middle cerebral artery diameter.
Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig.
Phosphodiesterase-5 inhibitors and migraine.
Role of Ser102 and Ser104 as regulators of cGMP hydrolysis by PDE5A.
Sildenafil can trigger cluster headaches.
Mitral Valve Stenosis
[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]
Mononeuropathies
Treatment Algorithms in Systemic Lupus Erythematosus.
Multiple Sclerosis
Drugs that Can Kill a Toddler with One Tablet or Teaspoonful: A 2018 Updated List.
Efficacy and Safety of Tadalafil for Erectile Dysfunction in Patients with Multiple Sclerosis.
Phoshphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?
Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis.
Muscle Spasticity
New therapies for non-cardiac chest pain.
Two Distinct Types of Hypercontractile Esophagus: Classic and Spastic Jackhammer.
Muscle Weakness
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
Muscular Atrophy
Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
Muscular Diseases
Bilateral Knee and Intermittent Elbow Pain in a Competitive Archer/Hunter: Phosphodiesterase-5-Inhibitor-Statin Interaction?
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.
Muscular Dystrophies
Efficacy of Phosphodiesterase 5 inhibitor on distant burn-induced muscle autophagy, microcirculation and survival rate.
Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.
Muscular Dystrophy, Duchenne
PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy.
Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Sildenafil and Cardioprotection.
Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.
Myalgia
A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia.
Rhabdomyolysis induced by rosuvastatin and sildenafil.
Mydriasis
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
Myocardial Infarction
Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study.
Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Identification of a Functional PDE5A Variant at the Chromosome 4q27 Coronary Artery Disease Locus in an Extended Myocardial Infarction Family.
Letter by Cingolani et al regarding article, "Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice".
Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review.
Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4.
Phosphodiesterase 5 inhibition- induced coronary vasodilation is reduced after myocardial infarction.
Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice.
Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
Serum cyclic 3',5'-nucleotide phosphodiesterase activity in myocardial infarction.
Sexual dysfunction in medical practice.
Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.
The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.
Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.
[Adenoviral short hairpin RNA targeting phosphodiesterase 5 attenuates cardiac remodeling and cardiac dysfunction following myocardial infarction in mice].
Myocardial Ischemia
Cicletanine attenuates overdrive pacing-induced global myocardial ischemia in rabbits: possible role of cardiac cyclic nucleotides.
Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation.
Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease.
Sildenafil augments early protective transcriptional changes after ischemia in mouse myocardium.
The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia.
Neoplasm Metastasis
Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer.
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
Neoplasm, Residual
Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range.
Neoplasms
67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis.
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and ?-catenin transcriptional activity.
Activation of protein kinase G Increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1.
An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies.
Apoptosis induction of poly-S-nitrosated human serum albumin in resistant solid tumor under hypoxia can be restored by phosphodiesterase 5 inhibition.
Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor?
cGMP phosphodiesterase activity evaluation in human carcinoma of salivary glands.
cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells.
Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.
Does cyclic guanosine monophosphate induce autophagy in thyroid malignant carcinoma through down-regulation of cyclic guanosine monophosphate phosphodiesterase?
Drug-induced hearing loss.
Endothelial Actions of ANP Enhance Myocardial Inflammatory Infiltration in the Early Phase After Acute Infarction.
Exisulind Cell Pathways.
Hard times for oncogenic BRAF-expressing melanoma cells.
Identification of potential genes in upper tract urothelial carcinoma using next-generation sequencing with bioinformatics and in vitro analyses.
Increased guanylate cyclase activity and guanosine 3',5'-monophosphate content in ethionine-induced hepatomas.
Inhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468.
Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities.
Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure-Based Drug Design Approach.
Modulators of arginine metabolism support cancer immunosurveillance.
MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs.
Neratinib augments the lethality of [regorafenib?+?sildenafil].
Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells.
No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma.
PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.
PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types.
PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model.
Pharmacological Modulation of Cytotoxicity and Cellular Uptake of Anti-cancer Drugs by PDE5 Inhibitors in Lung Cancer Cells.
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.
Phosphodiesterase type 5 and cancers: progress and challenges.
Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia.
Psychological Impacts of Male Sexual Dysfunction in Pelvic Cancer Survivorship.
Recovery of Baseline Erectile Function in Men Following Radical Prostatectomy for High-Risk Prostate Cancer: A Prospective Analysis Using Validated Measures.
Repurposing mechanistic insight of PDE-5 inhibitor in cancer chemoprevention through mitochondrial-oxidative stress intervention and blockade of DuCLOX signalling.
Retinoblastoma. A clinical, immunohistochemical, and electron microscopic case report.
Roles of sildenafil in enhancing drug sensitivity in cancer.
Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells.
Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.
Sildenafil inhibits the up-regulation of phosphodiesterase type 5 elicited with nicotine and tumour necrosis factor-alpha in cavernosal vascular smooth muscle cells: mediation by superoxide.
Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2.
Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-?Is), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence.
Sulindac and its derivatives: a novel class of anticancer agents.
Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/?-Catenin Signaling.
Suppression of Cavernosal Fibrosis in a Rat Model.
Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells.
Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.
Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective.
Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
Tadalafil Reverses the Effect of Three-Dimensional Cell Culture System on Stem Cell Features in A549 and SK-MES-1.
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression.
The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.
The Potential Role of Sildenafil in Cancer Management through EPR Augmentation.
Topological polar surface area: a useful descriptor in 2D-QSAR.
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
[Recurrence-free survival after radical prostatectomy and PDE-5 inhibitor intake].
Nephrotic Syndrome
Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat.
Nervous System Diseases
The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors.
Neuralgia
Effect of sildenafil on neuropathic pain and hemodynamics in rats.
Phoshphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?
The regulation of sGC on the rat model of neuropathic pain is mediated by 5-HT1ARs and NO/cGMP pathway.
Neuroblastoma
Differences and similarities between guanosine 3',5'-cyclic monophosphate phosphodiesterase and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in neuroblastoma cells in culture.
Role of Ser102 and Ser104 as regulators of cGMP hydrolysis by PDE5A.
Neurodegenerative Diseases
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Role of sildenafil in neurological disorders.
Neuroinflammatory Diseases
Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice.
Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition.
Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5.
Night Blindness
A truncated form of rod photoreceptor PDE6 ?-subunit causes autosomal dominant congenital stationary night blindness by interfering with the inhibitory activity of the ?-subunit.
Gene for autosomal dominant congenital stationary night blindness maps to the same region as the gene for the beta-subunit of the rod photoreceptor cGMP phosphodiesterase (PDEB) in chromosome 4p16.3.
Heterozygous missense mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant stationary night blindness.
Identification and functional characterization of a novel rhodopsin mutation associated with autosomal dominant CSNB.
Longitudinal Clinical Follow-up and Genetic Spectrum of Patients With Rod-Cone Dystrophy Associated With Mutations in PDE6A and PDE6B.
Missense mutation in the gene encoding the alpha subunit of rod transducin in the Nougaret form of congenital stationary night blindness.
Molecular genetics of Oguchi disease, fundus albipunctatus, and other forms of stationary night blindness: LVII Edward Jackson Memorial Lecture.
Mutation in rod PDE6 linked to congenital stationary night blindness impairs the enzyme inhibition by its gamma-subunit.
Retinal imaging in inherited retinal diseases.
Stationary night blindness or progressive retinal degeneration in mice carrying different alleles of PDE gamma.
Transgenic mice carrying the H258N mutation in the gene encoding the beta-subunit of phosphodiesterase-6 (PDE6B) provide a model for human congenital stationary night blindness.
Obesity
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Phosphodiesterase 5 inhibitor ameliorates renal resistance to atrial natriuretic Peptide associated with obesity and hyperleptinemia.
Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding.
Ocular Hypertension
NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys.
Optic Nerve Diseases
Acute onset of bilateral visual loss during sildenafil therapy in a young infant with congenital heart disease.
Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Non-arteritic anterior ischaemic optic neuropathy and phosphodiesterase-5 inhibitors.
Nonarteritic anterior ischaemic optic neuropathy.
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction.
Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case.
Optic neuropathy associated with the use of over-the-counter sexual enhancement supplements.
Post-Marketing Surveillance of Ischaemic Optic Neuropathy in Male Veterans Co-Prescribed Phosphodiesterase-5 Inhibitors with Organic Nitrates or alpha-Blockers.
Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis.
Toxic optic neuropathies: an updated review.
Optic Neuropathy, Ischemic
Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy.
Cases of Ischemic Optic Neuropathy Associated With Phosphodiesterase-5 Inhibitor Use Reported to the Food and Drug Administration Adverse Event Reporting System.
Drug-induced ocular disorders.
Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Literature commentary.
Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Non-arteritic anterior ischemic optic neuropathy, PDE-5 inhibitors, and amiodarone: may there be a sex hormone effect for the eye?
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction.
Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality?
Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?
Prospective Case-Crossover Study Investigating the Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Phosphodiesterase Type 5 Inhibitor (PDE5i) Exposure.
Rates of non-arteritic ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Sequential, non-arteritic anterior ischemic optic neuropathy in patients taking sildenafil: a report of ten cases.
Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.
The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.
The Relationship Between Phosphodiesterase-5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy.
Urologic medications and ophthalmologic side effects: a review.
Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.
[Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)]
Osteonecrosis
Phosphodiesterase-5 inhibition improves bone regeneration at the early stages of ischemic osteonecrosis of the femoral head in rats.
Osteoporosis
Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis.
Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease.
The NO-cGMP-PKG pathway in skeletal remodeling.
[The pathology of ocular syndromes caused by toxicity]
Ototoxicity
Effect of phosphodiesterase-5 inhibitor on hearing.
Phosphodiesterase-5 (PDE-5) Inhibitors and Ototoxicity: A Systematic Review.
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Parkinson Disease
Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease.
Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease.
Penile Induration
Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.
Expression of myosin isoforms in the smooth muscle of human corpus cavernosum.
Peyronie's disease: evolving surgical management and the role of phosphodiesterase 5 inhibitors.
Peyronie's disease: new paradigm for the treatment of a unique cause of erectile dysfunction.
Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.
Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.
The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.
Pericarditis
Treatment Algorithms in Systemic Lupus Erythematosus.
Peripheral Arterial Disease
Improvement in symptoms of peripheral arterial disease with sildenafil therapy.
Peripheral Nervous System Diseases
Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice.
MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions.
PDE5 inhibitors in diabetic peripheral neuropathy.
Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice.
Sildenafil Ameliorates Long Term Peripheral Neuropathy in Type II Diabetic Mice.
Tadalafil Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice.
The role of miR-146a in dorsal root ganglia neurons of experimental diabetic peripheral neuropathy.
Peripheral Vascular Diseases
Intracavernous delivery of Dickkopf3 gene or peptide rescues erectile function through enhanced cavernous angiogenesis in the diabetic mouse.
PDE5 inhibitors in diabetic peripheral neuropathy.
Recent advances in the treatment of systemic sclerosis.
Pheochromocytoma
Nerve growth factor increases the cyclic GMP level and activates the cyclic GMP phosphodiesterase in PC12 cells.
Photophobia
Drug-induced ocular disorders.
Occupancy of the chromophore binding site of opsin activates visual transduction in rod photoreceptors.
Purification and characterization of S-modulin, a calcium-dependent regulator on cGMP phosphodiesterase in frog rod photoreceptors.
Reversible bilateral subfoveal ellipsoid zone focal thickening associated with overdose of phosphodiesterase type 5 inhibitors intake.
[Effect of sildenafil citrate on the cortical visual responses]
Pneumonia
Lung fibrosis induced by crystalline silica particles is uncoupled from lung inflammation in NMRI mice.
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Polydactyly
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Pre-Eclampsia
A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia.
Different effects of different phosphodiesterase type-5 inhibitors in pre-eclampsia.
Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor.
Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries.
Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia.
Phosphodiesterase Inhibitor Effect on Small Artery Function in Preeclampsia.
Phosphodiesterase-5 inhibitors and omental and placental small artery function in normal pregnancy and pre-eclampsia.
Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Phosphodiesterases and preeclampsia.
Placental effects and transfer of sildenafil in healthy and preeclamptic conditions.
Sildenafil attenuates placental ischemia-induced hypertension.
Sildenafil Treatment Ameliorates the Maternal Syndrome of Preeclampsia and Rescues Fetal Growth in the Dahl Salt-Sensitive Rat.
Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.
Tadalafil alleviates preeclampsia and fetal growth restriction in RUPP model of preeclampsia in mice.
Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice.
The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report.
Prediabetic State
Undiagnosed prediabetes status is associated with a reduced effectiveness of phosphodiesterase type 5 inhibitors in men with erectile dysfunction.
Premature Birth
Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Premature Ejaculation
A randomized single-center study to compare the efficacy and tolerability of tadalafil once daily plus lidocaine anesthetic spray on premature ejaculation.
Advances in treating premature ejaculation.
Combination therapy with selective serotonin reuptake inhibitors and phosphodiesterase-5 inhibitors in the treatment of premature ejaculation.
Comparative efficacy and safety of phosphodiesterase-5 inhibitors with selective serotonin reuptake inhibitors in men with premature ejaculation: A systematic review and Bayesian network meta-analysis.
Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation.
Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.
Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study.
Efficacy and safety of phosphodiesterase type 5 inhibitors on primary premature ejaculation in men receiving selective serotonin reuptake inhibitors therapy: a systematic review and meta-analysis.
Efficacy of PDE5Is and SSRIs in men with premature ejaculation: a new systematic review and five meta-analyses.
Efficacy of Phosphodiesterase-5 Inhibitor in Men With Premature Ejaculation: A New Systematic Review and Meta-analysis.
Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review.
Interventions to Treat Erectile Dysfunction and Premature Ejaculation: An Overview of Systematic Reviews.
Lidocaine/prilocaine spray for premature ejaculation.
Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression.
Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation.
Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis.
Phosphodiesterase-5 inhibitors for premature ejaculation: a systematic review and meta-analysis.
Phosphodiesterase-5 Inhibitors for Premature Ejaculation: Systematic Review and Meta-Analysis of Placebo-Controlled Trials.
Re: Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study.
Selective Serotonin Reuptake Inhibitors Plus Phosphodiesterase-5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis.
Sexual Performance Anxiety.
Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study.
The Comparison of Combination SSRI and PDE-5 Inhibitor Therapy to SSRI Monotherapy in Men with Premature Ejaculation.
The Controversial Role of Phosphodiesterase Type 5 Inhibitors in the Treatment of Premature Ejaculation.
The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data.
[New data on the effectiveness of Tadalafil alone and in combination with NeyroDoz in treating erectile dysfunction associated with secondary premature ejaculation].
[Reflexions on 50 Years of Sexual Medicine in Urology Focusing on Male Sexual Dysfunctions].
[Treatment of premature ejaculation].
Priapism
Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Beneficial effect of the nitric oxide donor compound 3-(1,3-dioxoisoindolin-2-yl)benzyl nitrate on dysregulated phosphodiesterase 5, NADPH oxidase and nitrosative stress in the sickle cell mouse penis: implication for priapism treatment.
Castration for Treating Recurrent Priapism: Can We Do Better?
DAILY PHOSPHODIESTERASE TYPE-5 INHIBITOR THERAPY AS RESCUE FOR RECURRENT ISCHEMIC PRIAPISM AFTER FAILED ANDROGEN ABLATION: A CASE REPORT.
Daily tadalafil for the chronic phase of stuttering priapism: a case report.
Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism.
Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
Mechanisms underlying priapism in sickle cell disease: targeting and key innovations on the preclinical landscape.
Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review.
New Insights into the Pathophysiology of Sickle Cell Disease-Associated Priapism.
Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report.
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism.
Priapism and Sickle-Cell Anemia: Diagnosis and Nonsurgical Therapy.
Priapism in an Infant With Sickle Cell Trait After Cardiac Transplant.
Psychotropic-Induced Priapism in a Treatment-Refractory Patient: A Case Report.
Regimented Phosphodiesterase Type 5 Inhibitor Use Reduces Emergency Department Visits for Recurrent Ischemic Priapism.
Sickle cell trait and priapism: a case report and review of the literature.
Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress.
Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation.
Tissue expression, distribution, and regulation of PDE5.
Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature.
Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism.
Words of wisdom. Re: feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
Prostatic Hyperplasia
A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with ?-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Assessment of the effect of mirodenafil on the hemodynamics of healthy male korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study.
Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
Characterization of Phosphodiesterase Type 5 Expression and Functional Activity in the Human Male Lower Urinary Tract.
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Comorbid LUTS and erectile dysfunction: optimizing their management.
Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.
Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
Comparison of the Effects of Tadalafil and ?1-Adrenoceptor Antagonists on Spontaneous Seminal Emission and Electrical Field Stimulation-Induced Seminal Vesicle Contraction in Rats.
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis.
Effect of PDE-5 inhibitors on lower urinary tract symptoms in patients with benign prostatic hyperplasia.
Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US.
Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia.
Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies.
Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.
Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies.
EFFICIENCY OF SILDANEFIL MONOTHERAPY IN BENIGN PROSTATIC HYPERPLASIA.
Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue.
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors.
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
Lower Urinary Tract Symptoms: What's New in Medical Treatment?
Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.
Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.
Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors.
Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review.
Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate.
Phosphodiesterase Type 5 Inhibition Reverts Prostate Fibroblast-To-Myofibroblast Trans-Differentiation.
Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.
Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review.
Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia.
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats.
Re: A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
Re: Alpha-Blockers with or without Phosphodiesterase Type 5 Inhibitor for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with ?-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
Relaxation effect of phosphodiesterase-5 inhibitor on the animal bladder and prostatic urethra: in vitro and in vivo study.
Study of phosphodiesterase 5 inhibitors and ?-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and ?-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Tadalafil for benign prostatic hyperplasia.
Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
Tadalafil: A Phosphodiesterase-5 Inhibitor for Benign Prostatic Hyperplasia.
Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.
The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?
The Efficacy of PDE5 Inhibitors Alone or in Combination with Alpha-Blockers for the Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease.
The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History.
Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations.
Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.
Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia.
Vardenafil Decreases Bladder Afferent Nerve Activity in Unanesthetized, Decerebrate, Spinal Cord-Injured Rats.
[Combination of 1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction: results of observatory prospective multicenter study].
[Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia].
[Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction].
[Recent progress in basic research concerning the management of benign prostatic hyperplasia]
[Safety of tadalafil in patients with cardiovascular comorbidities].
[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
Prostatic Neoplasms
A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.
Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.
Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer.
Dickkopf2 rescues erectile function by enhancing penile neurovascular regeneration in a mouse model of cavernous nerve injury.
Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis.
Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial.
Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.
Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.
Long-term potency after early use of a vacuum erection device following radical prostatectomy.
Oral Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Improves Erectile Function in a Mouse Model of Cavernous Nerve Injury.
Over-expression of PDE5 in Oral Squamous Cell Carcinoma - Effect of Sildenafil Citrate.
Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway.
Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems.
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review.
Phosphodiesterase Type 5 Inhibitors Synergize Vincristine in Killing Castration-Resistant Prostate Cancer Through Amplifying Mitotic Arrest Signaling.
Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis.
Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line.
Phosphodiesterase-5 Inhibitors Could Be Efficacious in the Treatment of Erectile Dysfunction after Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
Predictors of response to sildenafil citrate following radiation therapy for prostate cancer.
Primary Care of the Prostate Cancer Survivor.
Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range.
Psychotherapy and phosphodiesterase-5 inhibitor in early rehabilitation after radical prostatectomy: a prospective randomised controlled trial.
Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men.
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy.
The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.
The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.
Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy.
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
Utilization of Pharmacotherapy for Erectile Dysfunction Following Treatment for Prostate Cancer.
[Urinary and sexual disorders following localised prostate cancer management].
Prostatitis
A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis.
Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: Effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain.
Comparison of tamsulosin vs tamsulosin/sildenafil effectiveness in the treatment of erectile dysfunction in patients affected by type III chronic prostatitis.
Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms.
[Experimental rodent models of chronic prostatitis: effect of phosphodiesterase 5 inhibitor on chronic pelvic-pain-related behavior].
[Wardenafil in combined treatment of patients with chronic bacterial prostatitis]
Proteinuria
Phosphodiesterase-5 gene (PDE5A) polymorphisms are associated with progression of childhood IgA nephropathy.
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Pseudorabies
Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass.
Psoriasis
Cyclic GMP metabolism in psoriasis: increased activity of soluble epidermal cyclic GMP phosphodiesterase and its modulation by calcium.
Pulmonary Arterial Hypertension
3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
A case of long-term sildenafil therapy in a young dog with pulmonary hypertension.
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.
A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension.
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.
A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension.
Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.
Acute, Bilateral, Concurrent Central Retinal Artery Occlusion in Sickle Cell Disease After Use of Tadalafil (Cialis).
Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
An evidence-based approach to the management of pulmonary arterial hypertension.
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study.
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).
Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Classical activation of macrophages and vardenafil.
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension.
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension.
Conversion From Sildenafil to Tadalafil: Results From the Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) Study.
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition.
Development and validation of a GC/MS method for the determination of tadalafil in whole blood.
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification.
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.
Effect of sildenafil citrate on brain central fatigue after exhaustive swimming exercise in rats.
Effect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in mice.
Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.
Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
Efficacy of Oral Tadalafil, a New Long-acting Phosphodiesterase-5 Inhibitor, for the Short-term Treatment of Pulmonary Arterial Hypertension in a Dog.
Emerging therapies for the treatment of pulmonary hypertension.
Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5).
Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension.
Future treatments in systemic sclerosis.
Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment.
High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.
Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies.
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE.
Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.
In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil.
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells.
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan.
Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.
Mechanisms Involved in the Remyelinating Effect of Sildenafil.
Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.
Medical treatment update on pulmonary arterial hypertension.
Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors.
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.
One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease.
Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension.
Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): A Randomized Controlled Trial.
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study): A Randomized Controlled Trial.
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.
Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension.
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Phosphodiesterase type 5 and high altitude pulmonary hypertension.
Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.
Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension.
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study.
Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis.
Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.
Pulmonary arterial hypertension.
Pulmonary Hypertension and HIV infection: epidemiology, pathogenesis, and clinical approach.
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.
Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.
Pulmonary hypertension in systemic lupus erythematosus.
Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Recent advances in the treatment of systemic sclerosis.
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.
Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
Reverse-phase high-performance liquid chromatography for the simultaneous determination of sildenafil and N-desmethyl sildenafil in plasma of children.
Review of inhaled iloprost for the control of pulmonary artery hypertension in children.
Right ventricular failure: a novel era of targeted therapy.
Safety and Efficacy of Ambrisentan-Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice.
Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension.
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Selexipag: A Review in Pulmonary Arterial Hypertension.
Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.
Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
Sildenafil for Pulmonary Arterial Hypertension.
Sildenafil for pulmonary arterial hypertension: when blue turns into white.
Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.
Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension.
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
Sildenafil: a review of its use in pulmonary arterial hypertension.
Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension.
Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension.
Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors.
Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report.
Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors.
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes.
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Tadalafil for benign prostatic hyperplasia.
Tadalafil for the treatment of pulmonary arterial hypertension.
Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment.
Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Tadalafil: in pulmonary arterial hypertension.
The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis.
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
The molecular targets of approved treatments for pulmonary arterial hypertension.
The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.
Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations.
Treatment Algorithms for Systemic Sclerosis According to Experts.
Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.
ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.
Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia.
Vardenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study.
Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.
[Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension.]
[Diagnosis and treatment of pulmonary hypertension].
[Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension].
[Emerging Therapies for the Treatment of Pulmonary Arterial Hypertension.]
[Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension]
[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension]
[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
[Pulmonary arterial hypertension]
[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors]
Pulmonary Disease, Chronic Obstructive
Hemodynamic and Gas Exchange Effects of Sildenafil in Patients with COPD and Pulmonary Hypertension.
Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.
Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial.
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.
Udenafil Improves Exercise Capacity in Patients with Chronic Obstructive Pulmonary Disease: A Prospective Study.
Pulmonary Edema
Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema.
Systematic Review of the Effects of Phosphodiesterase-5 Inhibitors and Dexamethasone on High Altitude Pulmonary Edema (HAPE).
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.
Pulmonary Embolism
Role of Phosphodiesterase-5 Inhibitors in Acute Right Ventricular Failure Due to Pulmonary Embolism.
Sildenafil improves the beneficial haemodynamic effects of intravenous nitrite infusion during acute pulmonary embolism.
Pulmonary Fibrosis
Differential expression of caveolin-1 during pathogenesis of combined pulmonary fibrosis and emphysema: Effect of phosphodiesterase-5 inhibitor.
PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.
Pulmonary Heart Disease
The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA).
Pulmonary Veno-Occlusive Disease
Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease.
Pyelonephritis
Preventive effect of phosphodiesterase 5 inhibitor Tadalafil on experimental post-pyelonephritic renal injury in rats.
Raynaud Disease
On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials.
PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials.
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.
Therapeutic options for digital ulcers in patients with systemic sclerosis.
[Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome]
Rectal Neoplasms
Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial.
Renal Insufficiency
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Renal Insufficiency, Chronic
Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage.
Potential Therapeutic Role of Phosphodiesterase Type 5 Inhibition in Hypertension and Chronic Kidney Disease.
The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease.
Reperfusion Injury
Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury.
Effect of the Phosphodiesterase-5 Inhibitor Zaprinast on Ischemia-Reperfusion Injury in Rats.
Effects of Sildenafil and Tadalafil on Edema and Reactive Oxygen Species Production in an Experimental Model of Lung Ischemia-Reperfusion Injury.
ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.
Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate.
Neuroprotective effect of tadalafil, a PDE-5 inhibitor, and its modulation by L-NAME in mouse model of ischemia-reperfusion injury.
Phosphodiesterase-5 inhibitor and rat lung ischemia-reperfusion injury.
Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.
Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G.
Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3{beta}.
sGC-cGMP-PKG pathway stimulation protects the healthy but not the failing right ventricle of rats against ischemia and reperfusion injury.
[Protective effect of tadalafil against ischemia-reperfusion injury in rats].
Respiratory Distress Syndrome
Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.
Respiratory Insufficiency
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
Retinal Degeneration
(3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one ameliorates retinal degeneration in Pde6b
A Natural Occurring Mouse Model with Adgrv1 Mutation of Usher Syndrome 2C and Characterization of its Recombinant Inbred Strains.
A Naturally-Derived Compound Schisandrin B Enhanced Light Sensation in the pde6c Zebrafish Model of Retinal Degeneration.
A simple polymerase chain reaction assay for genotyping the retinal degeneration mutation (Pdeb(rd1)) in FVB/N-derived transgenic mice.
Analysis and quantitation of mRNAs encoding the alpha- and beta-subunits of rod photoreceptor cGMP phosphodiesterase in neonatal retinal degeneration (rd) mouse retinas.
Analysis of PDE6D and PDE6G genes for generalised progressive retinal atrophy (gPRA) mutations in dogs.
Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa.
Atypical retinal degeneration 3 in mice is caused by defective PDE6B pre-mRNA splicing.
bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations.
Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis pigmentosa.
Caspase inhibition with XIAP as an adjunct to AAV vector gene-replacement therapy: improving efficacy and prolonging the treatment window.
Comprehensive Molecular Screening in Chinese Usher Syndrome Patients.
Cone neurite sprouting: an early onset abnormality of the cone photoreceptors in the retinal degeneration mouse.
Correction: A Naturally-Derived Compound Schisandrin B Enhanced Light Sensation in the pde6c Zebrafish Model of Retinal Degeneration.
Cyclic GMP phosphodiesterase activator: Involvement in a hereditary retinal degeneration.
Destructive Changes in the Neuronal Structure of the FVB/N Mouse Retina.
Divergent Effects of HSP70 Overexpression in Photoreceptors During Inherited Retinal Degeneration.
Dopamine receptor loss of function is not protective of rd1 rod photoreceptors in vivo.
Effects of the rd1 mutation and host strain on hippocampal learning in mice.
Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration.
Exchange of Cone for Rod Phosphodiesterase 6 Catalytic Subunits in Rod Photoreceptors Mimics in Part Features of Light Adaptation.
Expression profiling of the retina of pde6c, a zebrafish model of retinal degeneration.
Frequency of the codon 807 mutation in the cGMP phosphodiesterase beta-subunit gene in Irish setters and other dog breeds with hereditary retinal degeneration.
FVB.129P2-Pde6b(+) Tyr(c-ch)/Ant, a sighted variant of the FVB/N mouse strain suitable for behavioral analysis.
Gene therapy restores vision in rd1 mice after removal of a confounding mutation in Gpr179.
Genetic expression of cyclic GMP phosphodiesterase activity defines abnormal photoreceptor differentiation in neurological mutants of inherited retinal degeneration.
Genotype-phenotype correlation of mouse pde6b mutations.
Hippocampal synaptic plasticity in mice carrying the rd mutation in the gene encoding cGMP phosphodiesterase type 6 (PDE6).
Identification of a nonsense mutation in the rod photoreceptor cGMP phosphodiesterase beta-subunit gene of the rd mouse.
Inhibition of mTOR signaling by rapamycin protects photoreceptors from degeneration in rd1 mice.
Involvement of cyclic GMP phosphodiesterase activator in an hereditary retinal degeneration.
IQCB1 and PDE6B mutations cause similar early onset retinal degenerations in two closely related terrier dog breeds.
Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase.
Long-term effects of human induced pluripotent stem cell-derived retinal cell transplantation in Pde6b knockout rats.
Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa.
Molecular characterization and mapping of canine cGMP-phosphodiesterase delta subunit (PDE6D).
Neurotoxicity of cGMP in the vertebrate retina: from the initial research on rd mutant mice to zebrafish genetic approaches.
NIH Swiss and Black Swiss mice have retinal degeneration and performance deficits in cognitive tests.
Novel immunodeficient Pde6b rd1 mouse model of retinitis pigmentosa to investigate potential therapeutics and pathogenesis of retinal degeneration.
Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy.
Re-evaluation casts doubt on the pathogenicity of homozygous USH2A p.C759F.
Reduced rhodopsin phosphorylation during retinal dystrophy.
Restoration of Vision in the pde6?-deficient Dog, a Large Animal Model of Rod-cone Dystrophy.
Retinal Degeneration and rd1 Mutation in NC/Tnd Mice-A Human Atopic Dermatitis Model.
Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase.
Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase.
Retinal degeneration is rescued in transgenic rd mice by expression of the cGMP phosphodiesterase beta subunit.
Retinitis pigmentosa and retinal degeneration in animals: a review.
Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse.
Ribozyme knockdown of the gamma-subunit of rod cGMP phosphodiesterase alters the ERG and retinal morphology in wild-type mice.
RNA-Seq reveals differential expression profiles and functional annotation of genes involved in retinal degeneration in Pde6c mutant Danio rerio.
Screening of the gene encoding the alpha'-subunit of cone cGMP-PDE in patients with retinal degenerations.
Stationary night blindness or progressive retinal degeneration in mice carrying different alleles of PDE gamma.
The regulatory subunit of PDE6 interacts with PACSIN in photoreceptors.
Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene.
Up-regulation of tumor necrosis factor superfamily genes in early phases of photoreceptor degeneration.
Variable phenotypic expressivity in inbred retinal degeneration mouse lines: A comparative study of C3H/HeOu and FVB/N rd1 mice.
[Early changes in retinal 5'-nucleotidase activity in hereditary retinal degeneration]
Retinal Diseases
A novel method for objective vision testing in canine models of inherited retinal disease.
Analysis of six candidate genes as potential modifiers of disease expression in canine XLPRA1, a model for human X-linked retinitis pigmentosa 3.
Development of a Pde6b Gene Knockout Rat Model for Studies of Degenerative Retinal Diseases.
Exploring the Genetic Landscape of Retinal Diseases in North-Western Pakistan Reveals a High Degree of Autozygosity and a Prevalent Founder Mutation in ABCA4.
Genetic mapping demonstrates that the alpha-subunit of retinal cGMP-phosphodiesterase is not the site of the rd mutation.
Mechanisms of mutant PDE6 proteins underlying retinal diseases.
Transgenic mice carrying the H258N mutation in the gene encoding the beta-subunit of phosphodiesterase-6 (PDE6B) provide a model for human congenital stationary night blindness.
Retinal Dystrophies
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Animal models of human retinal dystrophies.
Identity-by-descent-guided mutation analysis and exome sequencing in consanguineous families reveals unusual clinical and molecular findings in retinal dystrophy.
Next-generation sequencing targeted disease panel in rod-cone retinal dystrophies in M?ori and Polynesian reveals novel changes and a common founder mutation.
Reduced rhodopsin phosphorylation during retinal dystrophy.
Retinitis Pigmentosa
A homozygous PDE6B mutation in a family with autosomal recessive retinitis pigmentosa.
A novel homozygous Ile535Asn mutation in the rod cGMP phosphodiesterase beta-subunit gene in two brothers of a Japanese family with autosomal recessive retinitis pigmentosa.
A novel intronic mutation of PDE6B is a major cause of autosomal recessive retinitis pigmentosa among Caucasus Jews.
AAV-mediated gene replacement either alone or in combination with physical and pharmacological agents results in partial and transient protection from photoreceptor degeneration associated with {beta}PDE deficiency.
Apoptosis, retinitis pigmentosa, and degeneration.
Autosomal recessive retinitis pigmentosa caused by mutations in the alpha subunit of rod cGMP phosphodiesterase.
Autosomal-recessive early-onset retinitis pigmentosa caused by a mutation in PDE6G, the gene encoding the gamma subunit of rod cGMP phosphodiesterase.
Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis pigmentosa.
Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line.
Clinical characteristics and disease progression of retinitis pigmentosa associated with PDE6B mutations in Korean patients.
Clinical Phenotype of PDE6B-Associated Retinitis Pigmentosa.
Confirmation of tyrosine 698 in beta subunit of cGMP phosphodiesterase in patients with retinitis pigmentosa and population of the west of Mexico.
Correction: Novel PDE6B Mutation Presenting with Retinitis Pigmentosa - A Case Series of Three Patients.
Erectile disfunction medical treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with retinitis pigmentosa and side effects.
Evidence for retinal remodelling in retinitis pigmentosa caused by PDE6B mutation.
Exclusion of the PDE6A gene for generalised progressive retinal atrophy in 11 breeds of dog.
Expanding the Clinical and Molecular Heterogeneity of Nonsyndromic Inherited Retinal Dystrophies.
Expression and characterization of human PDEdelta and its Caenorhabditis elegans ortholog CEdelta.
Frequency of mutations in the gene encoding the alpha subunit of rod cGMP-phosphodiesterase in autosomal recessive retinitis pigmentosa.
Genetic analysis of patients with retinitis pigmentosa using a cloned cDNA probe for the human gamma subunit of cyclic GMP phosphodiesterase.
Genetic heterogeneity and consanguinity lead to a "double hit": homozygous mutations of MYO7A and PDE6B in a patient with retinitis pigmentosa.
Genotype-phenotype correlation of mouse pde6b mutations.
In vivo genome editing rescues photoreceptor degeneration via a Cas9/RecA-mediated homology-directed repair pathway.
Lentivirus-mediated expression of cDNA and shRNA slows degeneration in retinitis pigmentosa.
Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa.
Membrane protein transport in photoreceptors: the function of PDE?: the Proctor lecture.
Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa.
Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa.
Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa.
Mutations in the PDE6B gene in autosomal recessive retinitis pigmentosa.
Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration.
Novel immunodeficient Pde6b rd1 mouse model of retinitis pigmentosa to investigate potential therapeutics and pathogenesis of retinal degeneration.
Novel mutations in PDE6B causing human retinitis pigmentosa.
Novel PDE6B Mutation Presenting with Retinitis Pigmentosa - A Case Series of Three Patients.
Photoreceptor cGMP phosphodiesterase delta subunit (PDEdelta) functions as a prenyl-binding protein.
Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa.
Reduced rod electroretinograms in carrier parents of two Japanese siblings with autosomal recessive retinitis pigmentosa associated with PDE6B gene mutations.
Restoration of Vision in the pde6?-deficient Dog, a Large Animal Model of Rod-cone Dystrophy.
Retinal remodeling.
Screening of the PDE6B gene in patients with autosomal dominant retinitis pigmentosa.
shRNA knockdown of guanylate cyclase 2e or cyclic nucleotide gated channel alpha 1 increases photoreceptor survival in a cGMP phosphodiesterase mouse model of retinitis pigmentosa.
Structural disease progression in PDE6-associated autosomal recessive retinitis pigmentosa.
The delta subunit of rod specific cyclic GMP phosphodiesterase, PDE delta, interacts with the Arf-like protein Arl3 in a GTP specific manner.
The gene therapy revolution in ophthalmology.
The retinitis pigmentosa GTPase regulator, RPGR, interacts with the delta subunit of rod cyclic GMP phosphodiesterase.
The search for mutations in the gene for the beta subunit of the cGMP phosphodiesterase (PDEB) in patients with autosomal recessive retinitis pigmentosa.
Therapeutic Margins in a Novel Preclinical Model of Retinitis Pigmentosa.
Transgenic mice carrying the H258N mutation in the gene encoding the beta-subunit of phosphodiesterase-6 (PDE6B) provide a model for human congenital stationary night blindness.
Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene.
[A study of PDE6B gene mutation and phenotype in Chinese cases with retinitis pigmentosa]
Retinoblastoma
Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6.
Expression of cone photoreceptor cGMP-phosphodiesterase alpha' subunit in Chinese hamster ovary, 293 human embryonic kidney, and Y79 retinoblastoma cells.
Expression of the functional cone phototransduction cascade in retinoblastoma.
Rod photoreceptor-specific gene expression in human retinoblastoma cells.
The human cGMP-PDE beta-subunit promoter region directs expression of the gene to mouse photoreceptors.
Retinoschisis
Retinal imaging in inherited retinal diseases.
Rhabdomyolysis
Bilateral Knee and Intermittent Elbow Pain in a Competitive Archer/Hunter: Phosphodiesterase-5-Inhibitor-Statin Interaction?
Rhinitis
[Rhinitis medicamentosa].
Rosacea
Phosphodiesterase-5 inhibitors and rosacea: report of 10 cases.
Schistosomiasis
Pulmonary vascular disease associated with schistosomiasis.
Scleroderma, Systemic
A clinical comparison of an endothelin receptor antagonist and phosphodiesterase-5 inhibitors for treating digital ulcers of systemic sclerosis.
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.
Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels.
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis.
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species.
Vasoactive therapies in systemic sclerosis.
[Pulmonary arterial hypertension in connective tissue diseases]
[Pulmonary arterial hypertension related to connective tissue diseases]
Scotoma
PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH PHOSPHODIESTERASE-5 INHIBITOR THERAPY.
Seizures
Effect of sildenafil, a selective phosphodiesterase 5 inhibitor, on the anticonvulsant action of some antiepileptic drugs in the mouse 6-Hz psychomotor seizure model.
Influence of sildenafil on the anticonvulsant action of selected antiepileptic drugs against pentylenetetrazole-induced clonic seizures in mice.
PDEI-5 for Erectile Dysfunction: A Potential Role in Seizure Susceptibility.
Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen.
Sildenafil influences the anticonvulsant activity of vigabatrin and gabapentin in the timed pentylenetetrazole infusion test in mice.
The interaction of sildenafil with the anticonvulsant effect of diazepam.
[Epileptic seizures and vardenafil]
Sepsis
Shedding of the tumor necrosis factor (TNF) receptor from the surface of hepatocytes during sepsis limits inflammation through cGMP signaling.
Sexually Transmitted Diseases
Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage?
Impact of phosphodiesterase type 5 inhibitor treatment on the rates of sexually transmitted diseases in a Veterans Affairs Medical Center patient population.
Sexually transmitted infection in HIV-positive men with erectile dysfunction using phosphodiesterase-5 inhibitors.
Shock, Cardiogenic
The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts.
Sickle Cell Trait
Sickle cell trait and priapism: a case report and review of the literature.
Silicosis
Tadalafil reduces airway hyperactivity and protects against lung and respiratory airways dysfunction in a rat model of silicosis.
Skin Neoplasms
Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans.
Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects.
Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-?Is), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence.
Systemic medications linked to an increased risk for skin malignancy.
Sleep Apnea, Obstructive
Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease.
Sphincter of Oddi Dysfunction
Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction.
Spinal Cord Diseases
Urinary and sexual manifestations of patients infected by HTLV-I.
Spinal Cord Injuries
Current diagnosis and management of erectile dysfunction.
Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
Effects of an alpha1A/D-adrenoceptor antagonist, naftopidil, and a phosphodiesterase type 5 inhibitor, tadalafil, on urinary bladder remodeling in rats with spinal cord injury.
Management of erectile dysfunction.
Reply to 'Efficacy and safety of phosphodiesterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis'.
Ten Years of Phosphodiesterase Type 5 Inhibitors in Spinal Cord Injured Patients.
The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury.
Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury.
[Subarachnoid hemorrhage due to autonomic dysreflexia : Rare consequence of sexual stimulation in a paraplegic.]
Spinal Dysraphism
Sexual dysfunction and infertility in the male spina bifida patient.
Spinal Stenosis
Phosphodiesterase 5 Inhibitor Use in Patients Undergoing Decompression Surgery for Lumbar Spinal Stenosis.
Squamous Cell Carcinoma of Head and Neck
Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
Stomach Neoplasms
[Relationship between cyclic nucleotide phosphodiesterases (cPDE) and some patho-biologic behaviors of stomach cancer--I. Histochemical studies of CPDE in stomach cancer tissues]
Stroke
A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats.
Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study.
Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.
Effects of the PDE5-inhibitor vardenafil in a mouse stroke model.
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor.
Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate.
Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat.
Novel phosphodiesterase-5 inhibitors: Current indications and future directions.
PDE5 INHIBITOR TREATMENT OPTIONS FOR UROLOGIC AND NON- UROLOGIC INDICATIONS: 2012 UPDATE.
PDE5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.
Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial.
Pituitary adenoma apoplexy associated with vardenafil intake.
Role of sildenafil in neurological disorders.
Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis.
Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats.
Sildenafil, a cyclic GMP phosphodiesterase inhibitor, induces microglial modulation after focal ischemia in the neonatal mouse brain.
Tadalafil may improve cerebral perfusion in small-vessel occlusion stroke-a pilot study.
Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
Targeting nitric oxide in the subacute restorative treatment of ischemic stroke.
Thymosin beta4: a candidate for treatment of stroke?
Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke.
Stuttering
Daily tadalafil for the chronic phase of stuttering priapism: a case report.
How I manage priapism due to sickle cell disease.
Priapism and Sickle-Cell Anemia: Diagnosis and Nonsurgical Therapy.
Tissue expression, distribution, and regulation of PDE5.
Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism.
Subarachnoid Hemorrhage
Acute Effect of Intravenous Sildenafil on Cerebral Blood Flow in Patients with Vasospasm After Subarachnoid Hemorrhage.
Acute Intracranial and Spinal Subdural Hematoma Associated with Vardenafil.
Effect of vardenafil on cerebral vasospasm following experimental subarachnoid hemorrhage in rats.
Nonaneurysmal Subarachnoid Hemorrhage after Udenafil Intake.
Phosphodiesterase 5 Inhibition Attenuates Cerebral Vasospasm and Improves Functional Recovery after Experimental Subarachnoid Hemorrhage.
Role of sildenafil in neurological disorders.
Syncope
Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review.
Thromboangiitis Obliterans
Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors.
Thrombosis
Increased bleeding risk with phosphodiesterase-5 inhibitors after left ventricular assist device implantation.
Inducing heat shock protein 70 expression provides a robust antithrombotic effect with minimal bleeding risk.
Reveals of candidate active ingredients in Justicia and its anti-thrombotic action of mechanism based on network pharmacology approach and experimental validation.
Thymoma
Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway.
Thyroid Neoplasms
Human thyroid cyclic nucleotide phosphodiesterase. Its characterization and the effect of several hormones on the activity.
PDE5 Inhibitors-Loaded Nanovesicles: Physico-Chemical Properties and In Vitro Antiproliferative Activity.
Thyroiditis, Subacute
Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
Tuberculosis
Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding likely to affect protein's function.
Univentricular Heart
Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design.
Ureteral Calculi
Efficacy and safety of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi of 5 to 10 mm in size: A systematic review and network meta-analysis.
Efficacy of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi: A systematic review and meta-analysis.
Ureteral Obstruction
Phosphodiesterase 5 inhibitors attenuate renal tubular apoptosis after partial unilateral ureteral obstruction: an experimental study.
Positive outcomes of phosphodiesterase type 5 inhibitor on histopathologic and biochemical changes induced by ureteral obstruction.
Urethral Obstruction
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity.
Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder.
Urethral Stricture
Effect of Tadalafil on Prevention of Urethral Stricture after Urethral Injury. an Experimental Study.
Urethral diverticulum after endoscopic urethrotomy: case report.
Urinary Bladder Diseases
Hydrogen Sulfide and Urogenital Tract.
Urinary Bladder Neck Obstruction
Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder.
Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats.
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
Effects of mirodenafil, a phosphodiesterase-5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model: physiological and immunohistochemical aspects.
Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction.
Evaluation of combined therapeutic effects of hydrogen sulfide donor sodium hydrogen sulfide and phosphodiesterase type-5 inhibitor tadalafil on erectile dysfunction in a partially bladder outlet obstructed rat model.
Long-term tadalafil administration can prevent functional and structural changes of the urinary bladder in male rats with partial bladder outlet obstruction.
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Urinary Bladder Neoplasms
Identification of potential genes in upper tract urothelial carcinoma using next-generation sequencing with bioinformatics and in vitro analyses.
Urinary Bladder, Neurogenic
Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors.
Urinary Bladder, Overactive
A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder.
Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder.
Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder.
Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients.
Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.
[Effects and mechanisms of phosphodiesterase type 5 inhibitors on rats with overactive bladder].
Urinary Bladder, Underactive
Urethral dysfunction and therapeutic effects of a PDE 5 inhibitor (tadalafil) in a rat model of detrusor underactivity induced by pelvic nerve crush injury.
Urinary Incontinence
[Urinary and sexual disorders following localised prostate cancer management].
Urination Disorders
[Combined treatment of patients with erectile dysfunction and urination disorders].
[Modern approaches to the treatment of patients with overactive bladder and urge urinary incontinence].
Urologic Diseases
Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.
Usher Syndromes
Genetic analysis of patients with retinitis pigmentosa using a cloned cDNA probe for the human gamma subunit of cyclic GMP phosphodiesterase.
The Time Course of Deafness and Retinal Degeneration in a Kunming Mouse Model for Usher Syndrome.
Uveitis
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Rapid affinity purification of retinal arrestin (48 kDa protein) via its light-dependent binding to phosphorylated rhodopsin.
Vascular Diseases
Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?
Intraurethral alprostadil for erectile dysfunction: a review of the literature.
Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
Mechanisms of C-peptide-mediated rescue of low O2-induced ATP release from erythrocytes of humans with Type 2 diabetes.
Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease.
Tadalafil for the treatment of pulmonary arterial hypertension.
Topical alprostadil cream for the treatment of erectile dysfunction.
Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
Vasculitis
Treatment Algorithms in Systemic Lupus Erythematosus.
Vasculitis, Central Nervous System
Treatment Algorithms in Systemic Lupus Erythematosus.
Vasospasm, Intracranial
Effect of vardenafil on cerebral vasospasm following experimental subarachnoid hemorrhage in rats.
Phosphodiesterase 5 Inhibition Attenuates Cerebral Vasospasm and Improves Functional Recovery after Experimental Subarachnoid Hemorrhage.
Venous Thrombosis
Treatment Algorithms in Systemic Lupus Erythematosus.
Ventricular Dysfunction, Left
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.
Ventricular Dysfunction, Right
Evaluation of Clinical Outcomes with Phosphodiesterase-5 Inhibitor Therapy for Right Ventricular Dysfunction After Left Ventricular Assist Device Implantation.
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Vision Disorders
Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
Generation of an induced pluripotent stem cell line (FRIMOi007-A) derived from an incomplete achromatopsia patient carrying a novel homozygous mutation in PDE6C gene.
Literature commentary.
Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.
Vitelliform Macular Dystrophy
Retinal imaging in inherited retinal diseases.
Whooping Cough
Functional modifications of transducin induced by cholera or pertussis-toxin-catalyzed ADP-ribosylation.
Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes.
Light activation of phospholipase A2 in rod outer segments of bovine retina and its modulation by GTP-binding proteins.
Nucleotide exchange and cGMP phosphodiesterase activation by pertussis toxin inactivated transducin.
Signal transduction via the B cell antigen receptor: involvement of a G protein and regulation of signaling.
Signaling of rat Frizzled-2 through phosphodiesterase and cyclic GMP.
The regulation of the cGMP-binding cGMP phosphodiesterase by proteins that are immunologically related to gamma subunit of the photoreceptor cGMP phosphodiesterase.